<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="72b1786a-3437-4799-8214-f37b5be5607c"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>These highlights do not include all the information needed to use ONIVYDE safely and effectively. See full prescribing information for ONIVYDE<br/>
      <br/> ONIVYDEÂ® (irinotecan liposome injection), for intravenous use<br/> Initial U.S. Approval: 1996</title>
   <effectiveTime value="20250303"/>
   <setId root="c8b58efa-1820-48a4-b70d-62918fc4abfc"/>
   <versionNumber value="9"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="118461578" root="1.3.6.1.4.1.519.1"/>
            <name>Ipsen Biopharmaceuticals, Inc.</name>
            <assignedEntity>
               <assignedOrganization>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="657484726" root="1.3.6.1.4.1.519.1"/>
                        <name>ScinoPharm Taiwan Ltd.</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C82401" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="API MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="15054-0043" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="527128525" root="1.3.6.1.4.1.519.1"/>
                        <name>Hubei Haosun Pharmaceuticals Co. Ltd</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C82401" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="API MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="15054-0043" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="502570286" root="1.3.6.1.4.1.519.1"/>
                        <name>Ipsen Pharma Biotech</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C43360" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="15054-0043" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="15054-0043" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84732" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="LABEL"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="15054-0043" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84731" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="PACK"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="15054-0043" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="181194176" root="1.3.6.1.4.1.519.1"/>
                        <name>Boston Analytical</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="15054-0043" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="071344167" root="1.3.6.1.4.1.519.1"/>
                        <name>Quality Chemical Laboratories (QCL)</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="15054-0043" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="079509111" root="1.3.6.1.4.1.519.1"/>
                        <name>Avista</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="15054-0043" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
               </assignedOrganization>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section ID="DLDE">
               <id root="6ac4b88b-8df7-466d-a22b-0b5888ed3c3e"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL PRODUCT DATA ELEMENTS SECTION"/>
               <effectiveTime value="20241227"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="15054-0043" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Onivyde</name>
                        <formCode code="C42974" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INJECTION, POWDER, FOR SOLUTION"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>IRINOTECAN HYDROCHLORIDE</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator value="4.3" unit="mg"/>
                              <denominator value="1" unit="mL"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="042LAQ1IIS" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>IRINOTECAN HYDROCHLORIDE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="7673326042" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>IRINOTECAN</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="043IPI2M0K" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>1,2-DISTEAROYL-SN-GLYCERO-3-PHOSPHOCHOLINE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="97C5T2UQ7J" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CHOLESTEROL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3L6NN8ZZKU" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM N-(CARBONYL-METHOXYPOLYETHYLENE GLYCOL 2000)-1,2-DISTEAROYL-SN-GLYCERO-3-PHOSPHOETHANOLAMINE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="RWW266YE9I" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYDROXYETHYLPIPERAZINE ETHANE SULFONIC ACID</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="451W47IQ8X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM CHLORIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="10" unit="mL"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43215" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="VIAL, SINGLE-DOSE"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="1" unit="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="15054-0043-1" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20151022"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA207793" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20151022"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38276" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INTRAVENOUS"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="BOX">
               <id root="0cd52a3c-b99a-40ae-a5d3-4f1e5add2b91"/>
               <code code="34066-1" codeSystem="2.16.840.1.113883.6.1" displayName="BOXED WARNING SECTION"/>
               <title>
                  <content styleCode="emphasis">WARNING: SEVERE NEUTROPENIA AND SEVERE DIARRHEA </content>
               </title>
               <text>
                  <paragraph>
                     <content styleCode="bold ">Neutropenia</content>
                  </paragraph>
                  <list listType="unordered" styleCode="disc">
                     <item>
                        <content styleCode="bold">Severe and life-threatening neutropenia, including fatal neutropenic sepsis and fatal neutropenic fever, has occurred in patients receiving ONIVYDE in combination with oxaliplatin, fluorouracil and leucovorin and in combination with fluorouracil and leucovorin.  Withhold ONIVYDE for absolute neutrophil count below 1500/mm<sup>3</sup> or neutropenic fever. Monitor blood cell counts periodically during treatment <content styleCode="italics">[see <linkHtml href="#S2.2">Dosage and Administration (2.2)</linkHtml> and <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml>].</content>
                        </content>
                     </item>
                  </list>
                  <paragraph>
                     <content styleCode="bold ">Diarrhea</content>
                  </paragraph>
                  <list listType="unordered" styleCode="disc">
                     <item>
                        <content styleCode="bold">Severe and life-threatening diarrhea has occurred in patients receiving ONIVYDE in combination with oxaliplatin, fluorouracil and leucovorin and in combination with fluorouracil and leucovorin. Do not administer ONIVYDE to patients with bowel obstruction. Withhold ONIVYDE for diarrhea of Grade 2-4 severity. Administer loperamide for late diarrhea of any severity. Administer atropine, if not contraindicated, for early diarrhea of any severity <content styleCode="italics">[see <linkHtml href="#S2.2">Dosage and Administration (2.2)</linkHtml> and <linkHtml href="#S5.2">Warnings and Precautions (5.2)</linkHtml>].</content>
                        </content>
                     </item>
                  </list>
               </text>
               <effectiveTime value="20241227"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>
                           <content styleCode="bold">WARNING: SEVERE NEUTROPENIA and SEVERE DIARRHEA</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold italics">See full prescribing information for complete boxed warning</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">Neutropenia</content>
                        </paragraph>
                        <list listType="unordered" styleCode="disc">
                           <item>
                              <content styleCode="bold">Severe or life-threatening neutropenia , including fatal neutropenic sepsis and fatal neutropenic fever, has occurred in patients receiving ONIVYDE in combination with oxaliplatin, fluorouracil and leucovorin and in combination with fluorouracil and leucovorin. Withhold ONIVYDE for absolute neutrophil count below 1500/mm<sup>3</sup> or neutropenic fever. Monitor blood cell counts periodically during treatment (<linkHtml href="#S2.2">2.2</linkHtml>), (<linkHtml href="#S5.1">5.1</linkHtml>).</content>
                           </item>
                        </list>
                        <paragraph>
                           <content styleCode="bold">Diarrhea</content>
                        </paragraph>
                        <list listType="unordered" styleCode="disc">
                           <item>
                              <content styleCode="bold">Severe and life-threatening diarrhea has occurred in patients receiving ONIVYDE in combination with oxaliplatin, fluorouracil and leucovorin and in combination with fluorouracil and leucovorin. Do not administer ONIVYDE to patients with bowel obstruction. Withhold ONIVYDE for diarrhea of Grade 2-4 severity. Administer loperamide for late diarrhea of any severity. Administer atropine, if not contraindicated, for early diarrhea of any severity (<linkHtml href="#S2.2">2.2</linkHtml>), (<linkHtml href="#S5.2">5.2</linkHtml>).</content>
                           </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section>
               <id root="7e9bde61-1181-4df9-aae2-073bf0fb3ad9"/>
               <code code="43683-2" codeSystem="2.16.840.1.113883.6.1" displayName="RECENT MAJOR CHANGES SECTION"/>
               <effectiveTime value="20241227"/>
               <excerpt>
                  <highlight>
                     <text>
                        <table width="100%" styleCode="Noautorules">
                           <col width="90%" align="left" valign="top"/>
                           <col width="10%" align="right" valign="top"/>
                           <tbody>
                              <tr>
                                 <td>Indications and Usage  (<linkHtml href="#S1">1</linkHtml>)</td>
                                 <td>02/2024</td>
                              </tr>
                              <tr>
                                 <td>Warnings and Precautions (<linkHtml href="#S5.1">5.1</linkHtml>, <linkHtml href="#S5.2">5.2</linkHtml>)</td>
                                 <td>02/2024</td>
                              </tr>
                              <tr>
                                 <td>Warnings and Precautions (<linkHtml href="#S5.3">5.3</linkHtml>)</td>
                                 <td>12/2024</td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S1">
               <id root="82da437f-df83-48c4-a43b-894009296366"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1 INDICATIONS AND USAGE</title>
               <text>
                  <list listType="unordered" styleCode="disc">
                     <item>
                        <content styleCode="xmChange">ONIVYDE is indicated, in combination with oxaliplatin, fluorouracil and leucovorin for the first-line treatment of adult patients with metastatic pancreatic adenocarcinoma.</content>
                     </item>
                     <item>ONIVYDE is indicated, in combination with fluorouracil and leucovorin, for the treatment of adult patients with metastatic pancreatic adenocarcinoma after disease progression following gemcitabine-based therapy.</item>
                  </list>
                  <paragraph>Limitations of Use: ONIVYDE is not indicated as a single agent for the treatment of patients with metastatic pancreatic adenocarcinoma. <content styleCode="italics">[see <linkHtml href="#S14">Clinical Studies (14)</linkHtml>]</content>.</paragraph>
               </text>
               <effectiveTime value="20241227"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>ONIVYDE is a topoisomerase inhibitor indicated:</paragraph>
                        <list listType="unordered" styleCode="disc">
                           <item>in combination with oxaliplatin, fluorouracil and leucovorin, for the first-line treatment of adult patients with metastatic pancreatic adenocarcinoma, (<linkHtml href="#S1">1</linkHtml>)</item>
                           <item>in combination with fluorouracil and leucovorin, for the treatment of adult patients with metastatic pancreatic adenocarcinoma after disease progression following gemcitabine-based therapy. (<linkHtml href="#S1">1</linkHtml>)</item>
                        </list>
                        <paragraph>Limitation of Use: ONIVYDE is not indicated as a single agent for the treatment of patients with metastatic pancreatic adenocarcinoma. (<linkHtml href="#S1">1</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S2">
               <id root="bca93077-8bf6-407a-8386-9d3af56c00ba"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2 DOSAGE AND ADMINISTRATION</title>
               <effectiveTime value="20241227"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="disc">
                           <item>
                              <content styleCode="bold">Do not substitute ONIVYDE for other drugs containing irinotecan HCl. (<linkHtml href="#S2.1">2.1</linkHtml>)</content>
                           </item>
                           <item>ONIVYDE in combination with oxaliplatin, fluorouracil and leucovorin:<list listType="unordered" styleCode="disc">
                                 <item>Recommended dose of ONIVYDE is 50 mg/m<sup>2</sup> intravenous infusion over 90 minutes every two weeks. (<linkHtml href="#S2.2">2.2</linkHtml>)</item>
                                 <item>Recommended starting dose of ONIVYDE in patients homozygous for UGT1A1*28 is 50 mg/m<sup>2</sup> every two weeks. (<linkHtml href="#S2.2">2.2</linkHtml>)</item>
                                 <item>There is no recommended dose of ONIVYDE for patients with serum bilirubin above the upper limit of normal. (<linkHtml href="#S2.2">2.2</linkHtml>)</item>
                              </list>
                           </item>
                           <item>ONIVYDE in combination with fluorouracil and leucovorin:<list listType="unordered" styleCode="disc">
                                 <item>Recommended dose of ONIVYDE is 70 mg/m<sup>2</sup> intravenous infusion over 90 minutes every two weeks. (<linkHtml href="#S2.2">2.2</linkHtml>)</item>
                                 <item>Recommended starting dose of ONIVYDE in patients homozygous for UGT1A1*28 is 50 mg/m<sup>2</sup> every two weeks. (<linkHtml href="#S2.2">2.2</linkHtml>) </item>
                                 <item>There is no recommended dose of ONIVYDE for patients with serum bilirubin above the upper limit of normal. (<linkHtml href="#S2.2">2.2</linkHtml>)</item>
                              </list>
                           </item>
                           <item>Premedicate with a corticosteroid and an anti-emetic 30 minutes prior to ONIVYDE. (<linkHtml href="#S2.2">2.2</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S2.1">
                     <id root="6a026b9f-1102-41b3-946e-2ed21f1a2cfe"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.1	 Important Use Information</title>
                     <text>
                        <paragraph>
                           <content styleCode="bold">DO NOT SUBSTITUTE</content> ONIVYDE for other drugs containing irinotecan HCl.</paragraph>
                     </text>
                     <effectiveTime value="20241227"/>
                  </section>
               </component>
               <component>
                  <section ID="S2.2">
                     <id root="3b4cf126-ff31-4e6b-9bf4-aa66c76f0dd0"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.2	 Recommended Dosage </title>
                     <effectiveTime value="20241227"/>
                     <component>
                        <section>
                           <id root="900fad76-d907-4a92-8f68-2f289ad755ff"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">In combination with oxaliplatin, fluorouracil and leucovorin for the first-line treatment of patients with metastatic pancreatic adenocarcinoma</content>
                              </paragraph>
                              <paragraph>Administer ONIVYDE prior to oxaliplatin, fluorouracil and leucovorin <content styleCode="italics">[see <linkHtml href="#S14">Clinical Studies (14)</linkHtml>]</content>.</paragraph>
                              <list listType="unordered" styleCode="disc">
                                 <item>The recommended dosage of ONIVYDE regardless of UGT1A1*28 allele genotype is 50 mg/m<sup>2</sup> administered by intravenous infusion over 90 minutes every 2 weeks.</item>
                                 <item>There is no recommended dosage of ONIVYDE for patients with serum bilirubin above the upper limit of normal <content styleCode="italics">[see <linkHtml href="#S6.1">Adverse Reactions (6.1)</linkHtml> and <linkHtml href="#S14">Clinical Studies (14)</linkHtml>].</content>
                                 </item>
                              </list>
                           </text>
                           <effectiveTime value="20241227"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="afffaca2-1498-47e4-aa20-2afe858bf422"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">In combination with fluorouracil and leucovorin for the treatment of patients with metastatic pancreatic adenocarcinoma after disease progression following gemcitabine-based therapy</content>
                              </paragraph>
                              <paragraph>Administer ONIVYDE prior to fluorouracil and leucovorin <content styleCode="italics">[see <linkHtml href="#S14">Clinical Studies (14)</linkHtml>]</content>.</paragraph>
                              <list listType="unordered" styleCode="disc">
                                 <item>The recommended dosage of ONIVYDE is 70 mg/m<sup>2</sup> administered by intravenous infusion over 90 minutes every 2 weeks.</item>
                                 <item>The recommended starting dose of ONIVYDE in patients known to be homozygous for the UGT1A1*28 allele is 50 mg/m<sup>2</sup> administered by intravenous infusion over 90 minutes. Increase the dose of ONIVYDE to 70 mg/m<sup>2</sup> as tolerated in subsequent cycles.</item>
                                 <item>There is no recommended dosage of ONIVYDE for patients with serum bilirubin above the upper limit of normal <content styleCode="italics">[see <linkHtml href="#S6.1">Adverse Reactions (6.1)</linkHtml> and <linkHtml href="#S14">Clinical Studies (14)</linkHtml>].</content>
                                 </item>
                              </list>
                           </text>
                           <effectiveTime value="20241227"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="ca00b765-4653-4ff5-8e18-e2cf74d4ad74"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Premedication</content>
                              </paragraph>
                              <paragraph>Administer a corticosteroid and an anti-emetic 30 minutes prior to each ONIVYDE infusion.</paragraph>
                           </text>
                           <effectiveTime value="20241227"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S2.3">
                     <id root="60e49b3a-2522-40c2-81e9-eb1699f7f81b"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.3	 Dosage Modifications for Adverse Reactions</title>
                     <text>
                        <paragraph>Recommended dosage modifications for ONIVYDE are in Table 1 and Table 2.</paragraph>
                        <table width="75%" ID="Table1">
                           <caption>Table 1	Recommended Dosage Modifications for ONIVYDE in combination with oxaliplatin, fluorouracil and leucovorin</caption>
                           <col width="32%" align="left" valign="middle"/>
                           <col width="34%" align="center" valign="middle"/>
                           <col width="34%" align="center" valign="middle"/>
                           <thead>
                              <tr>
                                 <th styleCode="Lrule Rrule" align="center" valign="top">Toxicity<footnote>Toxicity grading per NCI CTCAE v5.0.</footnote>
                                 </th>
                                 <th styleCode="Rrule" valign="top">Occurrence</th>
                                 <th styleCode="Rrule" valign="top">ONIVYDE adjustment in patients receiving 50mg/m<sup>2</sup>
                                 </th>
                              </tr>
                           </thead>
                           <tbody>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" rowspan="5">
                                    <content styleCode="bold">Grade 3 or 4 Adverse reactions<footnote>No dosage modification is necessary for asthenia, alopecia and Grade 3 anorexia.</footnote>
                                    </content>
                                 </td>
                                 <td styleCode="Rrule Botrule" colspan="2">Withhold ONIVYDE<br/>Upon recovery to â¤ Grade 1<footnote>Do not resume until the absolute neutrophil count is â¥2000/mm<sup>3</sup> (2Ã10<sup>9</sup>/L) and the platelet count is â¥100,000/mm<sup>3</sup> (100Ã10<sup>9</sup>/L).</footnote>,<footnote>For Grade â¥3 nausea and vomiting, reduce dose only if occurs despite optimal anti-emetic therapy.</footnote>,<footnote>Refer to the Full Prescribing Information of fluorouracil and oxaliplatin. When ONIVYDE dose is reduced for adverse reactions, reduce fluorouracil (FU) and oxaliplatin doses: for first occurrence, reduce dose to 80% of original dose; for second occurrence, reduce dose to 65% of original dose; for third occurrence, reduce dose to 50% of original dose; discontinue therapy for fourth occurrence. Oxaliplatin may be discontinued if not well tolerated and treatment with ONIVYDE + FU/LV can continue<content styleCode="italics">.</content> Maintain original dose level of leucovorin for first, second and third occurrence of toxicity.</footnote>, resume ONIVYDE at:</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Rrule" align="center">First</td>
                                 <td styleCode="Rrule">40 mg/m<sup>2</sup>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Rrule" align="center">Second</td>
                                 <td styleCode="Rrule">32.5 mg/m<sup>2</sup>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Rrule" align="center">Third</td>
                                 <td styleCode="Rrule">25 mg/m<sup>2</sup>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Rrule" align="center">Fourth</td>
                                 <td styleCode="Rrule">Discontinue ONIVYDE</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">
                                    <content styleCode="bold">Grade 3 or 4 Hand foot syndrome</content>
                                 </td>
                                 <td styleCode="Rrule">First</td>
                                 <td styleCode="Rrule">Discontinue ONIVYDE</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">
                                    <content styleCode="bold">Any grade neurocerebellar toxicity</content>
                                 </td>
                                 <td styleCode="Rrule">First</td>
                                 <td styleCode="Rrule">Discontinue ONIVYDE</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">
                                    <content styleCode="bold">Grade â¥ 2 cardiac toxicity</content>
                                 </td>
                                 <td styleCode="Rrule">First</td>
                                 <td styleCode="Rrule">Discontinue ONIVYDE</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule">
                                    <content styleCode="bold">Interstitial lung disease</content>
                                 </td>
                                 <td styleCode="Rrule">First</td>
                                 <td styleCode="Rrule">Discontinue ONIVYDE</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule">
                                    <content styleCode="bold">Anaphylactic reaction</content>
                                 </td>
                                 <td styleCode="Rrule">First</td>
                                 <td styleCode="Rrule">Discontinue ONIVYDE</td>
                              </tr>
                           </tbody>
                        </table>
                        <table width="75%" ID="Table2">
                           <caption>Table 2	Recommended Dosage Modifications for ONIVYDE in combination with fluorouracil and leucovorin</caption>
                           <col width="22%" align="left" valign="middle"/>
                           <col width="26%" align="center" valign="middle"/>
                           <col width="26%" align="center" valign="middle"/>
                           <col width="26%" align="center" valign="middle"/>
                           <thead>
                              <tr>
                                 <th styleCode="Lrule Rrule" align="center">Toxicity NCI CTCAE v4.0<footnote>NCI CTCAE v 4.0=National Cancer Institute Common Toxicity Criteria for Adverse Events version 4.0</footnote>
                                 </th>
                                 <th styleCode="Rrule">Occurrence</th>
                                 <th styleCode="Rrule">ONIVYDE adjustment in patients receiving 70 mg/m<sup>2</sup>
                                 </th>
                                 <th styleCode="Rrule">Patients homozygous for UGT1A1*28 without previous increase to 70 mg/m<sup>2</sup>
                                 </th>
                              </tr>
                           </thead>
                           <tbody>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" rowspan="4">
                                    <content styleCode="bold">Grade 3 or 4 adverse reactions </content>
                                 </td>
                                 <td styleCode="Rrule Botrule" colspan="3" align="left">Withhold ONIVYDE. <br/>Upon recovery to â¤ Grade 1, resume ONIVYDE at:</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Rrule" align="center">First</td>
                                 <td styleCode="Rrule">50 mg/m<sup>2</sup>
                                 </td>
                                 <td styleCode="Rrule">43 mg/m<sup>2</sup>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Rrule" align="center">Second</td>
                                 <td styleCode="Rrule">43 mg/m<sup>2</sup>
                                 </td>
                                 <td styleCode="Rrule">35 mg/m<sup>2</sup>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Rrule" align="center">Third</td>
                                 <td styleCode="Rrule">Discontinue ONIVYDE</td>
                                 <td styleCode="Rrule">Discontinue ONIVYDE</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">
                                    <content styleCode="bold">Interstitial Lung Disease</content>
                                 </td>
                                 <td styleCode="Rrule">First</td>
                                 <td styleCode="Rrule">Discontinue ONIVYDE</td>
                                 <td styleCode="Rrule">Discontinue ONIVYDE</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule">
                                    <content styleCode="bold">Anaphylactic Reaction</content>
                                 </td>
                                 <td styleCode="Rrule">First</td>
                                 <td styleCode="Rrule">Discontinue ONIVYDE</td>
                                 <td styleCode="Rrule">Discontinue ONIVYDE</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>For recommended dose modifications of fluorouracil (FU) or leucovorin (LV), refer to the Full Prescribing Information; refer to <linkHtml href="#s14">Clinical Studies (14)</linkHtml>.</paragraph>
                     </text>
                     <effectiveTime value="20241227"/>
                  </section>
               </component>
               <component>
                  <section ID="S2.4">
                     <id root="b84f6637-71af-4b1e-a0ee-b080b3b4551d"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.4	 Preparation and Administration</title>
                     <text>
                        <paragraph>ONIVYDE is a hazardous drug. Follow applicable special handling and disposal procedures.<sup>1</sup>
                        </paragraph>
                     </text>
                     <effectiveTime value="20241227"/>
                     <component>
                        <section>
                           <id root="9a6a592f-6681-4fd0-805f-29af10bd2618"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Preparation</content>
                              </paragraph>
                              <list listType="unordered" styleCode="disc">
                                 <item>Withdraw the calculated volume of ONIVYDE from the vial. Dilute ONIVYDE in 500 mL 5% Dextrose Injection, USP or 0.9% Sodium Chloride Injection, USP and mix diluted solution by gentle inversion. Discard vials with any unused portion.</item>
                                 <item>Protect diluted solution from light. </item>
                                 <item>Administer diluted solution within 4 hours of preparation when stored at room temperature or within 24 hours of preparation when stored under refrigerated conditions [2ÂºC to 8ÂºC (36ÂºF to 46ÂºF)]. Allow diluted solution to come to room temperature prior to administration.</item>
                                 <item>Do NOT freeze.</item>
                              </list>
                           </text>
                           <effectiveTime value="20241227"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="7eed5968-0144-4afd-99df-f42e8471c677"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Administration</content>
                              </paragraph>
                              <list listType="unordered" styleCode="disc">
                                 <item>Infuse diluted solution intravenously over 90 minutes.  </item>
                              </list>
                           </text>
                           <effectiveTime value="20241227"/>
                        </section>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S3">
               <id root="05e59653-3024-4ff3-bc6a-8fcef91f5c29"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3 DOSAGE FORMS AND STRENGTHS</title>
               <text>
                  <paragraph>Injection: 43 mg/10 mL irinotecan free base as a white to slightly yellow, opaque, liposomal dispersion in a single-dose vial.</paragraph>
               </text>
               <effectiveTime value="20241227"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Injection: 43 mg/10 mL (4.3 mg/mL) single dose vial (<linkHtml href="#S3">3</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S4">
               <id root="7dbdd5cf-22bc-4305-b8c6-d9c286ee4854"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4 CONTRAINDICATIONS</title>
               <text>
                  <paragraph>ONIVYDE is contraindicated in patients who have experienced a severe hypersensitivity reaction or anaphylaxis to ONIVYDE or irinotecan HCl. <content styleCode="italics">[see <linkHtml href="#S5.4">Warnings and Precautions (5.4)</linkHtml>, <linkHtml href="#S6.2">Adverse Reactions (6.2)</linkHtml>].</content>
                  </paragraph>
               </text>
               <effectiveTime value="20241227"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Severe hypersensitivity reaction to ONIVYDE or irinotecan HCl. (<linkHtml href="#S4">4</linkHtml>, <linkHtml href="#S5.4">5.4</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S5">
               <id root="2f42902d-7ed1-47da-9e0c-5948a2f24cbb"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5 WARNINGS AND PRECAUTIONS</title>
               <effectiveTime value="20241227"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="disc">
                           <item>Interstitial lung disease (ILD): Fatal ILD has occurred in patients receiving irinotecan including ONIVYDE. Discontinue ONIVYDE if ILD is diagnosed. (<linkHtml href="#S5.3">5.3</linkHtml>)</item>
                           <item>Severe hypersensitivity reaction: Permanently discontinue ONIVYDE for severe hypersensitivity reactions. (<linkHtml href="#S5.4">5.4</linkHtml>, <linkHtml href="#S4">4</linkHtml>)</item>
                           <item>Embryo-fetal toxicity: Can cause fetal harm. Advise females of reproductive potential of the potential risk to a fetus and to use effective contraception. (<linkHtml href="#S5.5">5.5</linkHtml>, <linkHtml href="#S8.1">8.1</linkHtml>, <linkHtml href="#S8.3">8.3</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S5.1">
                     <id root="e488668b-d494-45e0-9a0a-84276abef0ef"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.1	Severe Neutropenia</title>
                     <text>
                        <paragraph>ONIVYDE can cause severe or life-threatening neutropenia and fatal neutropenic sepsis.</paragraph>
                        <paragraph>
                           <content styleCode="xmChange">In NAPOLI 3, Grade 3 and 4 neutropenia occurred in 26% of patients receiving ONIVYDE in combination with oxaliplatin, fluorouracil, and leucovorin (NALIRIFOX) and fatal neutropenic fever in 0.3% of patients <content styleCode="italics">[see <linkHtml href="#S6.1">Adverse Reactions (6.1)</linkHtml>].</content> In NAPOLI-1, Grade 3 and 4 neutropenia occurred in 20% of patients receiving ONIVYDE in combination with fluorouracil and leucovorin (ONIVYDE/FU/LV). Neutropenic sepsis occurred in 3% and fatal neutropenic sepsis in 0.8% <content styleCode="italics">[see <linkHtml href="#S6.1">Adverse Reactions (6.1)</linkHtml>].</content>
                           </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="xmChange">In NAPOLI 3, the incidence of Grade 3 or 4 neutropenia was similar among Asian patients [6 of 20 (30%)] compared to White patients [76 of 289 (26%)] receiving ONIVYDE in combination with oxaliplatin, fluorouracil, and leucovorin. Neutropenic fever was reported in 5% of Asian patients (1 of 20) compared to 2.3% of White patients (7 of 306). In NAPOLI-1, the incidence of Grade 3 or 4 neutropenia was higher among Asian patients [18 of 33 (55%)] compared to White patients [13 of 73 (18%)] receiving ONIVYDE/FU/LV. Neutropenic fever/neutropenic sepsis was reported in 6% of Asian patients compared to 1% of White patients <content styleCode="italics">[see <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>].</content>
                           </content>
                        </paragraph>
                        <paragraph>Monitor complete blood cell counts on Days 1 and 8 of every cycle and more frequently if clinically indicated. Withhold ONIVYDE if the absolute neutrophil count (ANC) is below 1500/mm<sup>3</sup> or if neutropenic fever occurs. Resume ONIVYDE when the ANC is 1500/mm<sup>3</sup> or above. Reduce ONIVYDE dose for Grade 3-4 neutropenia or neutropenic fever following recovery in subsequent cycles <content styleCode="italics">[see <linkHtml href="#S2.2">Dosage and Administration (2.2)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20241227"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.2">
                     <id root="98f6f436-e7bb-484e-a7e3-4bf06b760bcc"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.2	Severe Diarrhea</title>
                     <text>
                        <paragraph>ONIVYDE can cause severe and life-threatening diarrhea. Do not administer ONIVYDE to patients with a bowel obstruction. Severe or life-threatening diarrhea can follow one of two patterns: late onset diarrhea (onset more than 24 hours following chemotherapy) and early onset diarrhea (onset within 24 hours of chemotherapy, sometimes occurring with other symptoms of cholinergic reaction) <content styleCode="italics">[see <linkHtml href="#S6.1">Adverse Reactions (6.1)</linkHtml>]</content>. An individual patient may experience both early and late-onset diarrhea. 								</paragraph>
                        <paragraph>
                           <content styleCode="xmChange">In NAPOLI 3, Grade 3 and 4 diarrhea (early and late-onset) occurred in 20% receiving ONIVYDE in combination with oxaliplatin, fluorouracil, and leucovorin (NALIRIFOX). In NAPOLI-1, Grade 3 or 4 diarrhea occurred in 13% receiving ONIVYDE/FU/LV. The incidence of Grade 3 or 4 late onset diarrhea was 9% in patients receiving ONIVYDE/FU/LV. The incidence of Grade 3 or 4 early onset diarrhea was 3% in patients receiving ONIVYDE/FU/LV. Of patients receiving ONIVYDE/FU/LV in NAPOLI-1, 34% received loperamide for late-onset diarrhea and 26% received atropine for early-onset diarrhea.</content>
                        </paragraph>
                        <paragraph>To reduce the risk of severe diarrhea, patients should stop lactose-containing products, eat a low-fat diet and maintain hydration during treatment with ONIVYDE. Withhold ONIVYDE for Grade 2-4 diarrhea. Administer intravenous or subcutaneous atropine 0.25 to 1 mg (unless clinically contraindicated) for early onset diarrhea of any severity. Initiate loperamide for late onset diarrhea of any severity. Local institutional guidelines should be followed for the treatment of diarrhea that does not improve within 48 hours and may include the addition of diphenoxylate hydrochloride plus atropine sulfate or octreotide. Following recovery to Grade 1 diarrhea, resume ONIVYDE at a reduced dose <content styleCode="italics">[see <linkHtml href="#S2.3">Dosage and Administration (2.3)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20241227"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.3">
                     <id root="2bebc9e6-7fbe-43c2-a6c2-ffbe770a9b83"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.3	Interstitial Lung Disease</title>
                     <text>
                        <paragraph>
                           <content styleCode="xmChange">ONIVYDE can cause severe and fatal interstitial lung disease (ILD), including pneumonitis. Postmarketing cases of severe and fatal ILD have been reported with ONIVYDE. Risk factors include pre-existing lung disease, use of pneumotoxic medicinal products, colony stimulating factors or having previously received radiation therapy. Patients with risk factors should be closely monitored for respiratory symptoms before and during ONIVYDE therapy. Withhold ONIVYDE in patients with new or progressive dyspnea, cough, and fever, pending diagnostic evaluation. Discontinue ONIVYDE in patients with a confirmed diagnosis of ILD.</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20241227"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.4">
                     <id root="5a42623d-b698-431b-a4c2-3648a50dd31c"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.4	Severe Hypersensitivity Reaction</title>
                     <text>
                        <paragraph>Irinotecan including ONIVYDE can cause severe hypersensitivity reactions, including anaphylactic reactions. Permanently discontinue ONIVYDE in patients who experience a severe hypersensitivity reaction <content styleCode="italics">[see <linkHtml href="#S4">Contraindications (4)</linkHtml>, <linkHtml href="#S6.2">Adverse reactions (6.2)</linkHtml>].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20241227"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.5">
                     <id root="8caa1e0a-1804-4951-9721-2fabe498a7b6"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.5	 Embryo-Fetal Toxicity</title>
                     <text>
                        <paragraph>Based on animal data with irinotecan HCl and the mechanism of action of ONIVYDE, ONIVYDE can cause fetal harm when administered to a pregnant woman. Embryotoxicity and teratogenicity were observed following treatment with irinotecan HCl, at doses resulting in irinotecan exposures lower than those achieved with ONIVYDE 70 mg/m<sup>2</sup> in humans, administered to pregnant rats and rabbits during organogenesis. Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with ONIVYDE and for seven months following the last dose <content styleCode="italics">[see <linkHtml href="#S8.1">Use in Specific Populations (8.1</linkHtml>, <linkHtml href="#S8.3">8.3)</linkHtml>, <linkHtml href="#S12.1">Clinical Pharmacology (12.1)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20241227"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S6">
               <id root="94599d76-c3e1-465f-8407-948a68ccb265"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6 ADVERSE REACTIONS</title>
               <text>
                  <paragraph>The following adverse drug reactions are discussed in greater detail in other sections of the label:</paragraph>
                  <list listType="unordered" styleCode="disc">
                     <item>Severe Neutropenia [see <content styleCode="italics">
                           <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml>]</content>
                     </item>
                     <item>Severe Diarrhea <content styleCode="italics">									[see <linkHtml href="#S5.2">Warnings and Precautions (5.2)</linkHtml>] 								</content>
                     </item>
                     <item>Interstitial Lung Disease <content styleCode="italics">[see <linkHtml href="#S5.3">Warnings and Precautions (5.3)</linkHtml>]</content>
                     </item>
                     <item>Severe Hypersensitivity Reactions <content styleCode="italics">[see <linkHtml href="#S5.4">Warnings and Precautions (5.4)</linkHtml>]</content>
                     </item>
                  </list>
               </text>
               <effectiveTime value="20241227"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>The most common adverse reactions (reported in â¥ 20% of patients) were for:</paragraph>
                        <list listType="unordered" styleCode="disc">
                           <item>ONIVYDE in combination with oxaliplatin, fluorouracil and leucovorin: diarrhea, fatigue, nausea, vomiting, decreased appetite, abdominal pain, mucosal inflammation, constipation, and decreased weight. The most common laboratory abnormalities (â¥ 10% Grade 3 or 4) were decreased neutrophils, decreased potassium, decreased lymphocytes, and decreased hemoglobin. (<linkHtml href="#S6.1">6.1</linkHtml>)</item>
                           <item>ONIVYDE in combination with fluorouracil and leucovorin: diarrhea, fatigue/asthenia, vomiting, nausea, decreased appetite, stomatitis, and pyrexia. The most common laboratory abnormalities (â¥ 10% Grade 3 or 4) were lymphopenia and neutropenia. (<linkHtml href="#S6.1">6.1</linkHtml>)</item>
                        </list>
                        <br/>
                        <paragraph>
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact Ipsen Biopharmaceuticals, Inc.at 1-855-463-5127 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch<content styleCode="italics">.</content>
                           </content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S6.1">
                     <id root="b9072755-796a-497f-9058-b5c657e4f3d1"/>
                     <code code="90374-0" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL TRIALS EXPERIENCE SECTION"/>
                     <title>6.1 Clinical Trials Experience</title>
                     <text>
                        <paragraph>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in clinical trials of ONIVYDE cannot be directly compared to rates in clinical trials of other drugs and may not reflect the rates observed in practice.</paragraph>
                     </text>
                     <effectiveTime value="20241227"/>
                     <component>
                        <section>
                           <id root="0356e77f-07fc-4311-9a6d-055bc6fbf254"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Pancreatic Adenocarcinoma</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20241227"/>
                           <component>
                              <section>
                                 <id root="45a097ac-218a-4fb2-b9bb-4b26fde1772e"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">In Combination with Oxaliplatin, Fluorouracil and Leucovorin for First-Line Treatment </content>
                                    </paragraph>
                                    <paragraph>The safety of ONIVYDE in patients with metastatic pancreatic adenocarcinoma who had not previously received chemotherapy was evaluated in NAPOLI 3 <content styleCode="italics">[see <linkHtml href="#S14">Clinical Studies (14)</linkHtml>]</content>. Patients received ONIVYDE 50 mg/m<sup>2</sup> in combination with oxaliplatin 60 mg/m<sup>2</sup>, leucovorin 400 mg/m<sup>2</sup> and fluorouracil 2400 mg/m<sup>2</sup> over 46 hours every 2 weeks (NALIRIFOX; N=383) or nab-paclitaxel 125 mg/m<sup>2</sup> over 35 minutes and gemcitabine 1000 mg/m<sup>2</sup> over 30 minutes on Day 1, 8 and 15 of each 28-day cycle (Gem+NabP; N=387). The median duration of exposure to ONIVYDE in combination with oxaliplatin, fluorouracil, and leucovorin was 24 weeks (range: 0 to 101 weeks).</paragraph>
                                    <paragraph>Serious adverse reactions occurred in 54% of patients who received ONIVYDE in combination with oxaliplatin, fluorouracil and leucovorin. Serious adverse reactions in â¥2% of patients included infections including COVID-19 (14%), diarrhea (9%), vomiting (6%), nausea (4.9%), fatigue (3.8%), embolism (3.5%), gastrointestinal tract stenosis or obstruction (3.5%), hemorrhage (3%), abdominal pain (2.7%), cerebrovascular accident (2.7%), dehydration (2.7%), liver function test abnormalities (2.2%), and pyrexia (2.2%). Fatal adverse reactions occurred in 6% of patients who received ONIVYDE in combination with oxaliplatin, fluorouracil and leucovorin including cerebrovascular accident (1.1%), hemorrhage (0.5%), pneumonia (0.5%), sepsis (0.5%) and sudden death (0.5%).</paragraph>
                                    <paragraph>Permanent discontinuation of ONIVYDE due to an adverse reaction occurred in 17% of patients. Adverse reactions which resulted in permanent discontinuation of ONIVYDE in â¥1% of patients included neutropenia, thrombocytopenia, diarrhea, fatigue, infections and cerebrovascular accident. </paragraph>
                                    <paragraph>Dosage reduction of ONIVYDE due to an adverse reaction occurred in 52% of patients. Adverse reactions which required dosage reduction in â¥1% of patients included anemia, decreased appetite, diarrhea, fatigue, febrile neutropenia, hypokalemia, liver function test abnormalities, nausea, mucosal inflammation, neutropenia, peripheral neuropathy, vomiting, thrombocytopenia and weight decreased.</paragraph>
                                    <paragraph>Dosage interruptions of ONIVYDE due to an adverse reaction occurred in 1.9% of patients. Adverse reactions which required dosage interruption in â¥0.5% of patients included hypersensitivity and infusion related reaction.</paragraph>
                                    <paragraph>The most common adverse reactions (â¥20% with a difference between arms of â¥ 5% for all grades or â¥ 2% for Grades 3 or 4 compared to Gem+NabP) of ONIVYDE in combination with oxaliplatin, fluorouracil, and leucovorin were diarrhea, fatigue, nausea, vomiting, decreased appetite, abdominal pain, mucosal inflammation, constipation and decreased weight. The most common laboratory abnormalities (â¥10% Grade 3 or 4) were decreased neutrophils, decreased potassium, decreased lymphocyte and decreased hemoglobin.</paragraph>
                                    <paragraph>Table 3 and 4 summarize the adverse reactions and laboratory abnormalities, respectively, in the NAPOLI 3 study.</paragraph>
                                    <table width="75%" ID="Table3">
                                       <caption>Table 3	Adverse Reactions<footnote ID="ft1">NCI CTCAE v5.0</footnote> (â¥ 20%) in Patients with Metastatic Pancreatic Adenocarcinoma who Received NALIRIFOX<footnote>NALIRIFOX=ONIVYDE+oxaliplatin/5-fluorouracil/leucovorin; Gem+NabP=gemcitabine+nab-paclitaxel</footnote> with a Difference Between Arms of â¥5% for All Grades or â¥ 2% for Grades 3 and 4 versus Gem+NabP in NAPOLI 3<footnoteRef IDREF="ft1"/>
                                       </caption>
                                       <col width="40%" align="left" valign="top"/>
                                       <col width="15%" align="center" valign="top"/>
                                       <col width="15%" align="center" valign="top"/>
                                       <col width="15%" align="center" valign="top"/>
                                       <col width="15%" align="center" valign="top"/>
                                       <thead>
                                          <tr>
                                             <th styleCode="Lrule Rrule" rowspan="2">Adverse Reaction</th>
                                             <th styleCode="Botrule Rrule" colspan="2" align="center">NALIRIFOX<br/>N=370</th>
                                             <th styleCode="Botrule Rrule" colspan="2">Gem+NabP<br/>N=379</th>
                                          </tr>
                                          <tr>
                                             <th styleCode="Rrule" align="center">All Grades<br/>(%)</th>
                                             <th styleCode="Rrule">Grade 3 or4<br/>(%)</th>
                                             <th styleCode="Rrule">All Grades<br/>(%)</th>
                                             <th styleCode="Rrule">Grade 3 or4<br/>(%)</th>
                                          </tr>
                                       </thead>
                                       <tbody>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule" colspan="5">
                                                <content styleCode="bold">Gastrointestinal disorders</content>
                                             </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Â Â Diarrhea<footnote ID="ft3">Includes multiple related terms</footnote>
                                             </td>
                                             <td styleCode="Rrule">72</td>
                                             <td styleCode="Rrule">22</td>
                                             <td styleCode="Rrule">37</td>
                                             <td styleCode="Rrule">5</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Â Â Nausea</td>
                                             <td styleCode="Rrule">59</td>
                                             <td styleCode="Rrule">12</td>
                                             <td styleCode="Rrule">43</td>
                                             <td styleCode="Rrule">2.6</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Â Â Vomiting<footnoteRef IDREF="ft3"/>
                                             </td>
                                             <td styleCode="Rrule">40</td>
                                             <td styleCode="Rrule">7</td>
                                             <td styleCode="Rrule">27</td>
                                             <td styleCode="Rrule">2.1</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Â Â Abdominal pain<footnoteRef IDREF="ft3"/>
                                             </td>
                                             <td styleCode="Rrule">35</td>
                                             <td styleCode="Rrule">4.3</td>
                                             <td styleCode="Rrule">25</td>
                                             <td styleCode="Rrule">4.7</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Â Â Constipation</td>
                                             <td styleCode="Rrule">25</td>
                                             <td styleCode="Rrule">0.8</td>
                                             <td styleCode="Rrule">30</td>
                                             <td styleCode="Rrule">2.1</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule" colspan="5">
                                                <content styleCode="bold">General disorders and administration site condition</content>
                                             </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Â Â Fatigue<footnoteRef IDREF="ft3"/>
                                             </td>
                                             <td styleCode="Rrule">62</td>
                                             <td styleCode="Rrule">15</td>
                                             <td styleCode="Rrule">63</td>
                                             <td styleCode="Rrule">10</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Â Â Mucosal inflammation<footnoteRef IDREF="ft3"/>
                                             </td>
                                             <td styleCode="Rrule">28</td>
                                             <td styleCode="Rrule">3.8</td>
                                             <td styleCode="Rrule">17</td>
                                             <td styleCode="Rrule">0.8</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Â Â Peripheral edema<footnoteRef IDREF="ft3"/>
                                             </td>
                                             <td styleCode="Rrule">16</td>
                                             <td styleCode="Rrule">0.3</td>
                                             <td styleCode="Rrule">34</td>
                                             <td styleCode="Rrule">2.4</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Â Â Pyrexia<footnoteRef IDREF="ft3"/>
                                             </td>
                                             <td styleCode="Rrule">11</td>
                                             <td styleCode="Rrule">0.8</td>
                                             <td styleCode="Rrule">24</td>
                                             <td styleCode="Rrule">1.6</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule" colspan="5">
                                                <content styleCode="bold">Investigations</content>
                                             </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Â Â Weight decreased</td>
                                             <td styleCode="Rrule">22</td>
                                             <td styleCode="Rrule">3</td>
                                             <td styleCode="Rrule">9</td>
                                             <td styleCode="Rrule">0.3</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule" colspan="5">
                                                <content styleCode="bold">Metabolism and nutrition disorders</content>
                                             </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Â Â Decreased appetite</td>
                                             <td styleCode="Rrule">37</td>
                                             <td styleCode="Rrule">9</td>
                                             <td styleCode="Rrule">28</td>
                                             <td styleCode="Rrule">2.6</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Â Â Dehydration</td>
                                             <td styleCode="Rrule">11</td>
                                             <td styleCode="Rrule">3.2</td>
                                             <td styleCode="Rrule">9</td>
                                             <td styleCode="Rrule">1.1</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule" colspan="5">
                                                <content styleCode="bold">Skin and subcutaneous tissue disorders</content>
                                             </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Â Â Alopecia</td>
                                             <td styleCode="Rrule">14</td>
                                             <td styleCode="Rrule">0</td>
                                             <td styleCode="Rrule">31</td>
                                             <td styleCode="Rrule">0.5</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Â Â Rash<footnoteRef IDREF="ft3"/>
                                             </td>
                                             <td styleCode="Rrule">11</td>
                                             <td styleCode="Rrule">0.3</td>
                                             <td styleCode="Rrule">22</td>
                                             <td styleCode="Rrule">1.6</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Â Â Nail disorder</td>
                                             <td styleCode="Rrule">0.3</td>
                                             <td styleCode="Rrule">0</td>
                                             <td styleCode="Rrule">7</td>
                                             <td styleCode="Rrule">0.3</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule" colspan="5">
                                                <content styleCode="bold">Vascular disorders</content>
                                             </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Â Â Hemorrhage<footnoteRef IDREF="ft3"/>
                                             </td>
                                             <td styleCode="Rrule">11</td>
                                             <td styleCode="Rrule">2.4</td>
                                             <td styleCode="Rrule">18</td>
                                             <td styleCode="Rrule">3.4</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Â Â Embolism<footnoteRef IDREF="ft3"/>
                                             </td>
                                             <td styleCode="Rrule">11</td>
                                             <td styleCode="Rrule">7</td>
                                             <td styleCode="Rrule">11</td>
                                             <td styleCode="Rrule">5</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule" colspan="5">
                                                <content styleCode="bold">Respiratory, thoracic and mediastinal disorders</content>
                                             </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Â Â Dyspnea<footnoteRef IDREF="ft3"/>
                                             </td>
                                             <td styleCode="Rrule">8</td>
                                             <td styleCode="Rrule">0.5</td>
                                             <td styleCode="Rrule">13</td>
                                             <td styleCode="Rrule">2.1</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule" colspan="5">
                                                <content styleCode="bold">Musculoskeletal and connective tissue disorders</content>
                                             </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Â Â Musculoskeletal pain<footnoteRef IDREF="ft3"/>
                                             </td>
                                             <td styleCode="Rrule">18</td>
                                             <td styleCode="Rrule">1.6</td>
                                             <td styleCode="Rrule">27</td>
                                             <td styleCode="Rrule">1.1</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule" colspan="5">
                                                <content styleCode="bold">Infections and infestations</content>
                                             </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Â Â Pneumonia</td>
                                             <td styleCode="Rrule">2.4</td>
                                             <td styleCode="Rrule">1.6</td>
                                             <td styleCode="Rrule">6</td>
                                             <td styleCode="Rrule">4</td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Lrule Rrule">Â Â Sepsis<footnoteRef IDREF="ft3"/>
                                             </td>
                                             <td styleCode="Rrule">1.6</td>
                                             <td styleCode="Rrule">1.1</td>
                                             <td styleCode="Rrule">6</td>
                                             <td styleCode="Rrule">3.4</td>
                                          </tr>
                                       </tbody>
                                    </table>
                                    <table width="75%" ID="Table4">
                                       <caption>Table 4	Laboratory Abnormalities in Patients with Metastatic Pancreatic Adenocarcinoma who Received NALIRIFOX<footnote>NALIRIFOX=ONIVYDE+oxaliplatin/5-fluorouracil/leucovorin ; Gem+NabP=gemcitabine+nab-paclitaxel</footnote> with a difference between arms of â¥ 5%  versus Gem+NabP in NAPOLI 3 <footnote>Each test incidence is based on the number of patients who had both baseline and at least one on-study laboratory measurement available: NALIRIFOX (range: 294 to 351 patients) and Gem+NabP (range: 303 to 373 patients).</footnote>
                                       </caption>
                                       <col width="40%" align="left" valign="top"/>
                                       <col width="15%" align="center" valign="top"/>
                                       <col width="15%" align="center" valign="top"/>
                                       <col width="15%" align="center" valign="top"/>
                                       <col width="15%" align="center" valign="top"/>
                                       <thead>
                                          <tr>
                                             <th styleCode="Lrule Rrule" rowspan="2">Laboratory abnormality</th>
                                             <th styleCode="Botrule Rrule" colspan="2" align="center">NALIRIFOX</th>
                                             <th styleCode="Botrule Rrule" colspan="2">Gem-NabP</th>
                                          </tr>
                                          <tr>
                                             <th styleCode="Rrule" align="center">All Grades<br/>(%)</th>
                                             <th styleCode="Rrule">Grade 3- or 4<br/>(%)</th>
                                             <th styleCode="Rrule">All Grades<br/>(%)</th>
                                             <th styleCode="Rrule">Grade 3 or4<br/>(%)</th>
                                          </tr>
                                       </thead>
                                       <tbody>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule" colspan="5">
                                                <content styleCode="bold">Hematology</content>
                                             </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Â Â Hemoglobin decreased</td>
                                             <td styleCode="Rrule">91</td>
                                             <td styleCode="Rrule">10</td>
                                             <td styleCode="Rrule">96</td>
                                             <td styleCode="Rrule">15</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Â Â Lymphocytes decreased</td>
                                             <td styleCode="Rrule">64</td>
                                             <td styleCode="Rrule">11</td>
                                             <td styleCode="Rrule">76</td>
                                             <td styleCode="Rrule">19</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Â Â Leukocytes decreased</td>
                                             <td styleCode="Rrule">62</td>
                                             <td styleCode="Rrule">8</td>
                                             <td styleCode="Rrule">77</td>
                                             <td styleCode="Rrule">28</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Â Â Neutrophils decreased</td>
                                             <td styleCode="Rrule">56</td>
                                             <td styleCode="Rrule">26</td>
                                             <td styleCode="Rrule">65</td>
                                             <td styleCode="Rrule">37</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Â Â Platelets decreased</td>
                                             <td styleCode="Rrule">55</td>
                                             <td styleCode="Rrule">1.7</td>
                                             <td styleCode="Rrule">75</td>
                                             <td styleCode="Rrule">7</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule" colspan="5">
                                                <content styleCode="bold">Hepatic</content>
                                             </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Â Â Alkaline phosphatase increased</td>
                                             <td styleCode="Rrule">45</td>
                                             <td styleCode="Rrule">2.9</td>
                                             <td styleCode="Rrule">35</td>
                                             <td styleCode="Rrule">2.7</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Â Â Alanine aminotransferase increased</td>
                                             <td styleCode="Rrule">40</td>
                                             <td styleCode="Rrule">2.6</td>
                                             <td styleCode="Rrule">56</td>
                                             <td styleCode="Rrule">4.6</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Â Â Aspartate aminotransferase increased</td>
                                             <td styleCode="Rrule">38</td>
                                             <td styleCode="Rrule">2</td>
                                             <td styleCode="Rrule">49</td>
                                             <td styleCode="Rrule">2.4</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule" colspan="5">
                                                <content styleCode="bold">Metabolic</content>
                                             </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Â Â Potassium decreased</td>
                                             <td styleCode="Rrule">62</td>
                                             <td styleCode="Rrule">22</td>
                                             <td styleCode="Rrule">29</td>
                                             <td styleCode="Rrule">8</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Â Â Sodium increased</td>
                                             <td styleCode="Rrule">11</td>
                                             <td styleCode="Rrule">0</td>
                                             <td styleCode="Rrule">5</td>
                                             <td styleCode="Rrule">0.3</td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Lrule Rrule">Â Â Potassium increased</td>
                                             <td styleCode="Rrule">8</td>
                                             <td styleCode="Rrule">0.6</td>
                                             <td styleCode="Rrule">21</td>
                                             <td styleCode="Rrule">3</td>
                                          </tr>
                                       </tbody>
                                    </table>
                                 </text>
                                 <effectiveTime value="20241227"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="95730ab8-562c-48f6-ac03-3e46370b2683"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">In Combination with Fluorouracil and Leucovorin after Progresssion on Gemcitabine or Gemcitabine-based Therapy</content>
                                    </paragraph>
                                    <paragraph>The safety data described below are derived from patients with metastatic pancreatic adenocarcinoma previously treated with gemcitabine-based therapy who received any part of protocol-specified therapy in NAPOLI-1, an international, randomized, active-controlled, open-label trial. Protocol-specified therapy consisted of ONIVYDE 70 mg/m<sup>2</sup> with leucovorin 400 mg/m<sup>2</sup> and fluorouracil 2400 mg/m<sup>2</sup> over 46 hours every 2 weeks (ONIVYDE/FU/LV; N=117), ONIVYDE 100 mg/m<sup>2</sup> every 3 weeks (N=147), or leucovorin 200 mg/m<sup>2</sup> and fluorouracil 2000 mg/m<sup>2</sup> over 24 hours weekly for 4 weeks followed by 2 week rest (FU/LV; N=134) <content styleCode="italics">[see <linkHtml href="#S14">Clinical Studies (14)</linkHtml>]</content>. Serum bilirubin within the institutional normal range, albumin â¥ 3 g/dL, and Karnofsky Performance Status (KPS) â¥ 70 were required for study entry. The median duration of exposure was 9 weeks in the ONIVYDE/FU/LV arm, 9 weeks in the ONIVYDE monotherapy arm, and 6 weeks in the FU/LV arm.</paragraph>
                                    <paragraph>The most common adverse reactions (â¥ 20%) of ONIVYDE were diarrhea, fatigue/asthenia, vomiting, nausea, decreased appetite, stomatitis, and pyrexia. The most common, severe laboratory abnormalities (â¥ 10% Grade 3 or 4) were lymphopenia and neutropenia. The most common serious adverse reactions (â¥ 2%) of ONIVYDE were diarrhea, vomiting, neutropenic fever or neutropenic sepsis, nausea, pyrexia, sepsis, dehydration, septic shock, pneumonia, acute renal failure, and thrombocytopenia.</paragraph>
                                    <paragraph>Adverse reactions led to permanent discontinuation of ONIVYDE in 11% of patients receiving ONIVYDE/FU/LV; the most frequent adverse reactions resulting in discontinuation of ONIVYDE were diarrhea, vomiting, and sepsis. Dose reductions of ONIVYDE for adverse reactions occurred in 33% of patients receiving ONIVYDE/FU/LV; the most frequent adverse reactions requiring dose reductions were neutropenia, diarrhea, nausea, and anemia. ONIVYDE was withheld or delayed for adverse reactions in 62% of patients receiving ONIVYDE/FU/LV; the most frequent adverse reactions requiring interruption or delays were neutropenia, diarrhea, fatigue, vomiting, and thrombocytopenia.</paragraph>
                                    <paragraph>Table 5 provides the frequency and severity of adverse reactions in NAPOLI-1 that occurred with higher incidence (â¥5% difference for Grades 1-4 or â¥2% difference for Grades 3-4) in patients who received ONIVYDE/FU/LV compared to patients who received FU/LV.</paragraph>
                                    <table width="75%" ID="Table5">
                                       <caption>Table 5	Adverse Reactions with Higher Incidence (â¥5% Difference for Grades 1-4<footnote>NCI CTCAE v4.0</footnote> or â¥2% Difference for Grades 3 and 4) in the ONIVYDE/FU/LV Arm </caption>
                                       <col width="40%" align="left" valign="top"/>
                                       <col width="15%" align="center" valign="top"/>
                                       <col width="15%" align="center" valign="top"/>
                                       <col width="15%" align="center" valign="top"/>
                                       <col width="15%" align="center" valign="top"/>
                                       <thead>
                                          <tr>
                                             <th styleCode="Lrule Rrule" valign="bottom">Adverse Reaction</th>
                                             <th styleCode="Botrule Rrule" colspan="2" align="center">ONIVYDE/FU/LV<br/>N=117</th>
                                             <th styleCode="Botrule Rrule" colspan="2">FU/LV<br/>N=134</th>
                                          </tr>
                                          <tr>
                                             <th styleCode="Lrule Rrule"/>
                                             <th styleCode="Rrule" align="center">Grades 1-4<br/>(%)</th>
                                             <th styleCode="Rrule">Grades 3-4<br/>(%)</th>
                                             <th styleCode="Rrule">Grades 1-4<br/>(%)</th>
                                             <th styleCode="Rrule">Grades 3-4 <br/>(%)</th>
                                          </tr>
                                       </thead>
                                       <tbody>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule" colspan="5">
                                                <content styleCode="bold">Gastrointestinal disorders</content>
                                             </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Â Â Diarrhea</td>
                                             <td styleCode="Rrule">59</td>
                                             <td styleCode="Rrule">13</td>
                                             <td styleCode="Rrule">26</td>
                                             <td styleCode="Rrule">4</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Â Â Â Â Early diarrhea<footnote>Early diarrhea: onset within 24 hours of ONIVYDE administration</footnote>
                                             </td>
                                             <td styleCode="Rrule">30</td>
                                             <td styleCode="Rrule">3</td>
                                             <td styleCode="Rrule">15</td>
                                             <td styleCode="Rrule">0</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Â Â Â Â Late diarrhea<footnote>Late diarrhea: onset &gt;1 day after ONIVYDE administration</footnote>
                                             </td>
                                             <td styleCode="Rrule">43</td>
                                             <td styleCode="Rrule">9</td>
                                             <td styleCode="Rrule">17</td>
                                             <td styleCode="Rrule">4</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Â Â Vomiting</td>
                                             <td styleCode="Rrule">52</td>
                                             <td styleCode="Rrule">11</td>
                                             <td styleCode="Rrule">26</td>
                                             <td styleCode="Rrule">3</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Â Â Nausea</td>
                                             <td styleCode="Rrule">51</td>
                                             <td styleCode="Rrule">8</td>
                                             <td styleCode="Rrule">34</td>
                                             <td styleCode="Rrule">4</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Â Â Stomatitis<footnote>Includes stomatitis, aphthous stomatitis, mouth ulceration, mucosal inflammation.</footnote>
                                             </td>
                                             <td styleCode="Rrule">32</td>
                                             <td styleCode="Rrule">4</td>
                                             <td styleCode="Rrule">12</td>
                                             <td styleCode="Rrule">1</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">
                                                <content styleCode="bold">Infections and infestations</content>
                                             </td>
                                             <td styleCode="Rrule">38</td>
                                             <td styleCode="Rrule">17</td>
                                             <td styleCode="Rrule">15</td>
                                             <td styleCode="Rrule">10</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Â Â Sepsis</td>
                                             <td styleCode="Rrule">4</td>
                                             <td styleCode="Rrule">3</td>
                                             <td styleCode="Rrule">2</td>
                                             <td styleCode="Rrule">1</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Â Â Neutropenic fever/neutropenic sepsis<footnote>Includes febrile neutropenia</footnote>
                                             </td>
                                             <td styleCode="Rrule">3</td>
                                             <td styleCode="Rrule">3</td>
                                             <td styleCode="Rrule">1</td>
                                             <td styleCode="Rrule">0</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Â Â Gastroenteritis</td>
                                             <td styleCode="Rrule">3</td>
                                             <td styleCode="Rrule">3</td>
                                             <td styleCode="Rrule">0</td>
                                             <td styleCode="Rrule">0</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Â Â Intravenous catheter-related infection</td>
                                             <td styleCode="Rrule">3</td>
                                             <td styleCode="Rrule">3</td>
                                             <td styleCode="Rrule">0</td>
                                             <td styleCode="Rrule">0</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule" colspan="5">
                                                <content styleCode="bold">General disorders and administration site conditions</content>
                                             </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Â Â Fatigue/asthenia</td>
                                             <td styleCode="Rrule">56</td>
                                             <td styleCode="Rrule">21</td>
                                             <td styleCode="Rrule">43</td>
                                             <td styleCode="Rrule">10</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Â Â Pyrexia</td>
                                             <td styleCode="Rrule">23</td>
                                             <td styleCode="Rrule">2</td>
                                             <td styleCode="Rrule">11</td>
                                             <td styleCode="Rrule">1</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule" colspan="5">
                                                <content styleCode="bold">Metabolism and nutrition disorders</content>
                                             </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Â Â Decreased appetite</td>
                                             <td styleCode="Rrule">44</td>
                                             <td styleCode="Rrule">4</td>
                                             <td styleCode="Rrule">32</td>
                                             <td styleCode="Rrule">2</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Â Â Weight loss</td>
                                             <td styleCode="Rrule">17</td>
                                             <td styleCode="Rrule">2</td>
                                             <td styleCode="Rrule">7</td>
                                             <td styleCode="Rrule">0</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Â Â Dehydration</td>
                                             <td styleCode="Rrule">8</td>
                                             <td styleCode="Rrule">4</td>
                                             <td styleCode="Rrule">7</td>
                                             <td styleCode="Rrule">2</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule" colspan="5">
                                                <content styleCode="bold">Skin and subcutaneous tissue disorders</content>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Lrule Rrule">Â Â Alopecia</td>
                                             <td styleCode="Rrule">14</td>
                                             <td styleCode="Rrule">1</td>
                                             <td styleCode="Rrule">5</td>
                                             <td styleCode="Rrule">0</td>
                                          </tr>
                                       </tbody>
                                    </table>
                                 </text>
                                 <effectiveTime value="20241227"/>
                              </section>
                           </component>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="e3e51ba4-7873-41fb-8b2b-0512a3646e5f"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>Other Adverse Reactions</paragraph>
                              <paragraph>Clinically relevant adverse reactions occurring in &lt;5% of patients include:</paragraph>
                           </text>
                           <effectiveTime value="20241227"/>
                           <component>
                              <section>
                                 <id root="4e56f04f-4998-4901-9dd3-cdddbb042cb5"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Cholinergic Reactions</content>: ONIVYDE can cause cholinergic reactions manifesting as rhinitis, increased salivation, flushing, bradycardia, miosis, lacrimation, diaphoresis, and intestinal hyperperistalsis with abdominal cramping and early onset diarrhea<content styleCode="italics">.</content> In NAPOLI-1, Grade 1 or 2 cholinergic symptoms other than early diarrhea occurred in 12 (4.5%) ONIVYDE-treated patients. Six of these 12 patients received atropine and in 1 of the 6 patients, atropine was administered for cholinergic symptoms other than diarrhea.</paragraph>
                                 </text>
                                 <effectiveTime value="20241227"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="e8fc004f-a93d-4431-994b-cb72c88b4a19"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Infusion Reactions</content>: Infusion reactions, consisting of rash, urticaria, periorbital edema, or pruritus, occurring on the day of ONIVYDE administration were reported in 3% of patients receiving ONIVYDE or ONIVYDE/FU/LV.</paragraph>
                                    <paragraph>Laboratory abnormalities that occurred with higher incidence in the ONIVYDE/FU/LV arm compared to the FU/LV arm (â¥5% difference) are summarized in the following table.</paragraph>
                                    <table width="75%" ID="Table6">
                                       <caption>Table 6	Laboratory Abnormalities with Higher Incidence (â¥5% Difference) in the ONIVYDE/FU/LV Arm<footnote>NCI CTCAE v4.0, worst grade shown.</footnote>
                                          <footnote>Percent based on number of patients with a baseline and at least one post-baseline measurement.</footnote>
                                       </caption>
                                       <col width="40%" align="left" valign="top"/>
                                       <col width="15%" align="center" valign="top"/>
                                       <col width="15%" align="center" valign="top"/>
                                       <col width="15%" align="center" valign="top"/>
                                       <col width="15%" align="center" valign="top"/>
                                       <thead>
                                          <tr>
                                             <th styleCode="Lrule Rrule" rowspan="2" valign="middle">Laboratory abnormality</th>
                                             <th styleCode="Botrule Rrule" colspan="2" align="center">ONIVYDE/FU/LV<br/>N=117</th>
                                             <th styleCode="Botrule Rrule" colspan="2">FU/LV<br/>N=134</th>
                                          </tr>
                                          <tr>
                                             <th styleCode="Rrule" align="center">Grades 1-4<br/>(%)</th>
                                             <th styleCode="Rrule">Grades 3-4<br/>(%)</th>
                                             <th styleCode="Rrule">Grades 1-4<br/>(%)</th>
                                             <th styleCode="Rrule">Grades 3-4 <br/>(%)</th>
                                          </tr>
                                       </thead>
                                       <tbody>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule" colspan="5">
                                                <content styleCode="bold">Hematology</content>
                                             </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Â Â Anemia</td>
                                             <td styleCode="Rrule">97</td>
                                             <td styleCode="Rrule">6</td>
                                             <td styleCode="Rrule">86</td>
                                             <td styleCode="Rrule">5</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Â Â Lymphopenia </td>
                                             <td styleCode="Rrule">81</td>
                                             <td styleCode="Rrule">27</td>
                                             <td styleCode="Rrule">75</td>
                                             <td styleCode="Rrule">17</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Â Â Neutropenia</td>
                                             <td styleCode="Rrule">52</td>
                                             <td styleCode="Rrule">20</td>
                                             <td styleCode="Rrule">6</td>
                                             <td styleCode="Rrule">2</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Â Â Thrombocytopenia</td>
                                             <td styleCode="Rrule">41</td>
                                             <td styleCode="Rrule">2</td>
                                             <td styleCode="Rrule">33</td>
                                             <td styleCode="Rrule">0</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule" colspan="5">
                                                <content styleCode="bold">Hepatic</content>
                                             </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Â Â Increased alanine aminotransferase (ALT)</td>
                                             <td styleCode="Rrule">51</td>
                                             <td styleCode="Rrule">6</td>
                                             <td styleCode="Rrule">37</td>
                                             <td styleCode="Rrule">1</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Â Â Hypoalbuminemia</td>
                                             <td styleCode="Rrule">43</td>
                                             <td styleCode="Rrule">2</td>
                                             <td styleCode="Rrule">30</td>
                                             <td styleCode="Rrule">0</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule" colspan="5">
                                                <content styleCode="bold">Metabolic</content>
                                             </td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Â Â Hypomagnesemia</td>
                                             <td styleCode="Rrule">35</td>
                                             <td styleCode="Rrule">0</td>
                                             <td styleCode="Rrule">21</td>
                                             <td styleCode="Rrule">0</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Â Â Hypokalemia</td>
                                             <td styleCode="Rrule">32</td>
                                             <td styleCode="Rrule">2</td>
                                             <td styleCode="Rrule">19</td>
                                             <td styleCode="Rrule">2</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Â Â Hypocalcemia</td>
                                             <td styleCode="Rrule">32</td>
                                             <td styleCode="Rrule">1</td>
                                             <td styleCode="Rrule">20</td>
                                             <td styleCode="Rrule">0</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Â Â Hypophosphatemia</td>
                                             <td styleCode="Rrule">29</td>
                                             <td styleCode="Rrule">4</td>
                                             <td styleCode="Rrule">18</td>
                                             <td styleCode="Rrule">1</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">Â Â Hyponatremia</td>
                                             <td styleCode="Rrule">27</td>
                                             <td styleCode="Rrule">5</td>
                                             <td styleCode="Rrule">12</td>
                                             <td styleCode="Rrule">3</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule" colspan="5">
                                                <content styleCode="bold">Renal</content>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Lrule Rrule">Â Â Increased creatinine</td>
                                             <td styleCode="Rrule">18</td>
                                             <td styleCode="Rrule">0</td>
                                             <td styleCode="Rrule">13</td>
                                             <td styleCode="Rrule">0</td>
                                          </tr>
                                       </tbody>
                                    </table>
                                 </text>
                                 <effectiveTime value="20241227"/>
                              </section>
                           </component>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S6.2">
                     <id root="c3f41327-bb35-4298-b294-bbafcf4c6e31"/>
                     <code code="90375-7" codeSystem="2.16.840.1.113883.6.1" displayName="POSTMARKETING EXPERIENCE SECTION"/>
                     <title>6.2 Postmarketing Experience</title>
                     <text>
                        <paragraph>The following adverse reactions have been identified during post approval use of ONIVYDE. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</paragraph>
                        <paragraph>
                           <content styleCode="bold">Immune system disorders:</content>  Hypersensitivity (including Anaphylactic reaction and Angioedema) </paragraph>
                     </text>
                     <effectiveTime value="20241227"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S7">
               <id root="6e9e8f61-3786-4e9e-9170-356eb5539ad3"/>
               <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
               <title>7 DRUG INTERACTIONS</title>
               <effectiveTime value="20241227"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="disc">
                           <item>Strong CYP3A4 Inducers: Avoid the use of strong CYP3A4 inducers if possible. Substitute non-enzyme inducing therapies at least 2 weeks prior to initiation of ONIVYDE. (<linkHtml href="#S7.1">7.1</linkHtml>)</item>
                           <item>Strong CYP3A4 Inhibitors: Avoid the use of strong CYP3A4 or UGT1A1 inhibitors, if possible; discontinue strong CYP3A4 inhibitors at least 1 week prior to starting therapy. (<linkHtml href="#S7.2">7.2</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S7.1">
                     <id root="b6764a09-0bde-4e51-808d-d0393ae19573"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.1	Strong CYP3A4 Inducers</title>
                     <text>
                        <paragraph>Following administration of non-liposomal irinotecan (i.e., irinotecan HCl), exposure to irinotecan or its active metabolite, SN-38, is substantially reduced in adult and pediatric patients concomitantly receiving the CYP3A4 enzyme-inducing anticonvulsants phenytoin and strong CYP3A4 inducers. Avoid the use of strong CYP3A4 inducers (e.g., rifampin, phenytoin, carbamazepine, rifabutin, rifapentine, phenobarbital, St. John's wort) if possible. Substitute non-enzyme inducing therapies at least 2 weeks prior to initiation of ONIVYDE therapy <content styleCode="italics">[see <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20241227"/>
                  </section>
               </component>
               <component>
                  <section ID="S7.2">
                     <id root="ecd97949-6b41-4746-849e-03a7ad23501b"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.2	Strong CYP3A4 or UGT1A1 Inhibitors</title>
                     <text>
                        <paragraph>Following administration of non-liposomal irinotecan (i.e., irinotecan HCl), patients receiving concomitant ketoconazole, a CYP3A4 and UGT1A1 inhibitor, have increased exposure to irinotecan and its active metabolite SN-38. Co-administration of ONIVYDE with other inhibitors of CYP3A4 (e.g., clarithromycin, indinavir, itraconazole, lopinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telaprevir, voriconazole) or UGT1A1 (e.g., atazanavir, gemfibrozil, indinavir) may increase systemic exposure to irinotecan or SN-38. Avoid the use of strong CYP3A4 or UGT1A1 inhibitors if possible. Discontinue strong CYP3A4 inhibitors at least 1 week prior to starting ONIVYDE therapy <content styleCode="italics">[see <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20241227"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S8">
               <id root="c0aecb8a-a983-4980-b193-048a1c292046"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8 USE IN SPECIFIC POPULATIONS</title>
               <effectiveTime value="20241227"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="disc">
                           <item>Lactation: Do not breastfeed. (<linkHtml href="#S8.2">8.2</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S8.1">
                     <id root="c4352307-74f9-43a6-a8ef-96269b4759a5"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>8.1 Pregnancy</title>
                     <effectiveTime value="20241227"/>
                     <component>
                        <section>
                           <id root="677aebbe-30a5-4054-ba68-d71290d0d782"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Risk Summary</content>
                              </paragraph>
                              <paragraph>Based on animal data with irinotecan HCl and the mechanism of action of ONIVYDE, ONIVYDE can cause fetal harm when administered to a pregnant woman <content styleCode="italics">[see <linkHtml href="#S12.1">Clinical Pharmacology (12.1)</linkHtml>]</content>. There are no available data in pregnant women. Embryotoxicity and teratogenicity were observed following treatment with irinotecan HCl, at doses resulting in irinotecan exposures lower than those achieved with ONIVYDE 70 mg/m<sup>2</sup> in humans, administered to pregnant rats and rabbits during organogenesis <content styleCode="italics">[see <linkHtml href="#Data1">Data</linkHtml>]</content>. Advise pregnant women of the potential risk to a fetus.</paragraph>
                              <paragraph>In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively.</paragraph>
                           </text>
                           <effectiveTime value="20241227"/>
                        </section>
                     </component>
                     <component>
                        <section ID="Data1">
                           <id root="b70b95f0-0820-4396-a63c-edd767cadd45"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Data</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20241227"/>
                           <component>
                              <section>
                                 <id root="80857f1d-6472-49c4-a5bb-09960e558b96"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Animal Data</content>
                                    </paragraph>
                                    <paragraph>No animal studies have been conducted to evaluate the effect of irinotecan liposome on reproduction and fetal development; however, studies have been conducted with irinotecan HCl. Irinotecan crosses the placenta of rats following intravenous administration. Intravenous administration of irinotecan at a dose of 6 mg/kg/day to rats and rabbits during the period of organogenesis resulted in increased post-implantation loss and decreased numbers of live fetuses. In separate studies in rats, this dose resulted in an irinotecan exposure of approximately 0.002 times the exposure of irinotecan based on area under the curve (AUC) in patients administered ONIVYDE at the 70 mg/m<sup>2</sup> dose. Administration of irinotecan HCl resulted in structural abnormalities and growth delays in rats at doses greater than 1.2 mg/kg/day (approximately 0.0002 times the clinical exposure to irinotecan in ONIVYDE based on AUC). Teratogenic effects included a variety of external, visceral, and skeletal abnormalities. Irinotecan HCl administered to rat dams for the period following organogenesis through weaning at doses of 6 mg/kg/day caused decreased learning ability and decreased female body weights in the offspring.</paragraph>
                                 </text>
                                 <effectiveTime value="20241227"/>
                              </section>
                           </component>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S8.2">
                     <id root="f8a87614-2248-43f1-880e-ee33afaf3bc3"/>
                     <code code="77290-5" codeSystem="2.16.840.1.113883.6.1" displayName="LACTATION SECTION"/>
                     <title>8.2 Lactation</title>
                     <effectiveTime value="20241227"/>
                     <component>
                        <section>
                           <id root="0e06800c-ce3c-4654-a948-b8c88c5a06f3"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Risk Summary</content>
                              </paragraph>
                              <paragraph>There is no information regarding the presence of irinotecan liposome, irinotecan, or SN-38 (an active metabolite of irinotecan) in human milk, or the effects on the breastfed infant or on milk production. Irinotecan is present in rat milk <content styleCode="italics">[see <linkHtml href="#Data2">Data</linkHtml>].</content>
                              </paragraph>
                              <paragraph>Because of the potential for serious adverse reactions in breastfed infants from ONIVYDE, advise a nursing woman not to breastfeed during treatment with ONIVYDE and for one month after the last dose.</paragraph>
                           </text>
                           <effectiveTime value="20241227"/>
                        </section>
                     </component>
                     <component>
                        <section ID="Data2">
                           <id root="dad38254-673a-4440-8d10-11d0f929fcc9"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Data</content>
                              </paragraph>
                              <paragraph>Radioactivity appeared in rat milk within 5 minutes of intravenous administration of radiolabeled irinotecan HCl and was concentrated up to 65-fold at 4 hours after administration relative to plasma concentrations.</paragraph>
                           </text>
                           <effectiveTime value="20241227"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S8.3">
                     <id root="98b28c4e-2d68-4198-8e68-a00d6bbc9159"/>
                     <code code="77291-3" codeSystem="2.16.840.1.113883.6.1" displayName="FEMALES &amp; MALES OF REPRODUCTIVE POTENTIAL SECTION"/>
                     <title>8.3 Females and Males of Reproductive Potential</title>
                     <effectiveTime value="20241227"/>
                     <component>
                        <section>
                           <id root="b9fbdab7-bede-44a2-a19c-1d7a09c9429f"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Contraception</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20241227"/>
                           <component>
                              <section>
                                 <id root="5edf487d-87bc-42bc-ace9-6b330fdc4b37"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Females</content>
                                    </paragraph>
                                    <paragraph>ONIVYDE can cause fetal harm when administered to a pregnant woman <content styleCode="italics">[see <linkHtml href="#S8.1">Use in Specific Populations (8.1)</linkHtml>].</content> Advise females of reproductive potential to use effective contraception during treatment with ONIVYDE and for seven months after the last dose.</paragraph>
                                 </text>
                                 <effectiveTime value="20241227"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="abc1c351-d955-40d9-a4fe-bf829ff49fbe"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Males</content>
                                    </paragraph>
                                    <paragraph>Because of the potential for genotoxicity, advise males with female partners of reproductive potential to use condoms during treatment with ONIVYDE and for four months after the last dose <content styleCode="italics">[see <linkHtml href="#S13.1">Nonclinical Toxicology (13.1)</linkHtml>].</content>
                                    </paragraph>
                                 </text>
                                 <effectiveTime value="20241227"/>
                              </section>
                           </component>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S8.4">
                     <id root="68f66be5-608a-4af6-b672-b864d9c782eb"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.4 Pediatric Use</title>
                     <text>
                        <paragraph>Safety and effectiveness of ONIVYDE have not been established in pediatric patients.</paragraph>
                     </text>
                     <effectiveTime value="20241227"/>
                  </section>
               </component>
               <component>
                  <section ID="S8.5">
                     <id root="971010e4-93b9-4fcb-b312-52bc83005b05"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>8.5 Geriatric Use</title>
                     <text>
                        <paragraph>Of the 634 patients who received ONIVYDE as a single agent, in combination with FU and leucovorin or in combination with oxaliplatin, FU and leucovorin in NAPOLI-1 and NAPOLI 3, 49% were â¥ 65 years old and 10% were â¥ 75 years old. No overall differences in safety and effectiveness were observed between these patients and younger patients.</paragraph>
                     </text>
                     <effectiveTime value="20241227"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S10">
               <id root="8b558c41-639c-4b67-904d-ea7ecc6398dc"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>10 OVERDOSAGE</title>
               <text>
                  <paragraph>There are no treatment interventions known to be effective for management of overdosage of ONIVYDE.</paragraph>
               </text>
               <effectiveTime value="20241227"/>
            </section>
         </component>
         <component>
            <section ID="S11">
               <id root="987de37c-210c-47fd-b252-8de487daaa04"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11 DESCRIPTION</title>
               <text>
                  <paragraph>ONIVYDE is formulated with irinotecan hydrochloride trihydrate, a topoisomerase inhibitor, into a liposomal dispersion for intravenous use. The chemical name of irinotecan hydrochloride trihydrate is (S)-4,11-diethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo1H-pyrano[3',4':6,7]-indolizino[1,2-b]quinolin-9-yl-[1,4'bipiperidine]-1'-carboxylate, monohydrochloride, trihydrate. The empirical formula is C<sub>33</sub>H<sub>38</sub>N<sub>4</sub>O<sub>6</sub>âHClâ3H<sub>2</sub>O and the molecular weight is 677.19 g/mole. The molecular structure is:</paragraph>
                  <renderMultiMedia referencedObject="MM1"/>
                  <paragraph>ONIVYDE is a sterile, white to slightly yellow opaque isotonic liposomal dispersion. Each 10 mL single-dose vial contains 43 mg irinotecan free base at a concentration of 4.3 mg/mL. The liposome is a unilamellar lipid bilayer vesicle, approximately 110 nm in diameter, which encapsulates an aqueous space containing irinotecan in a gelated or precipitated state as the sucrose octasulfate salt. The vesicle is composed of 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC) 6.81 mg/mL, cholesterol 2.22 mg/mL, and methoxy-terminated polyethylene glycol (MW 2000)-distearoylphosphatidyl ethanolamine (MPEG-2000-DSPE) 0.12 mg/mL. Each mL also contains 2-[4-(2-hydroxyethyl) piperazin-1-yl]ethanesulfonic acid (HEPES) as a buffer 4.05 mg/mL and sodium chloride as an isotonicity reagent 8.42 mg/mL.</paragraph>
               </text>
               <effectiveTime value="20241227"/>
               <component>
                  <observationMedia ID="MM1">
                     <text>Chemical Structure</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="onivyde-01.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="S12">
               <id root="c0544a19-12aa-4fba-95f3-de06d9056394"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12 CLINICAL PHARMACOLOGY</title>
               <effectiveTime value="20241227"/>
               <component>
                  <section ID="S12.1">
                     <id root="02c03e3c-a8c2-4e05-a1f2-db9bd97e6225"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>12.1 Mechanism of Action</title>
                     <text>
                        <paragraph>Irinotecan liposome injection is a topoisomerase 1 inhibitor encapsulated in a lipid bilayer vesicle or liposome. Topoisomerase 1 relieves torsional strain in DNA by inducing single-strand breaks. Irinotecan and its active metabolite SN-38 bind reversibly to the topoisomerase 1-DNA complex and prevent re-ligation of the single-strand breaks, leading to exposure time-dependent double-strand DNA damage and cell death. In mice bearing human tumor xenografts, irinotecan liposome administered at irinotecan HCl-equivalent doses 5-fold lower than irinotecan HCl achieved similar intratumoral exposure of SN-38.</paragraph>
                     </text>
                     <effectiveTime value="20241227"/>
                  </section>
               </component>
               <component>
                  <section ID="S12.3">
                     <id root="c7dc0e31-960b-49d6-aeb7-395e838c7ebe"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>12.3 Pharmacokinetics</title>
                     <text>
                        <paragraph>The plasma pharmacokinetics of total irinotecan and total SN-38 were evaluated in patients with cancer who received ONIVYDE, as a single agent or as part of combination chemotherapy, at doses between 35 mg/m<sup>2</sup> and 155 mg/m<sup>2</sup> and concentration proportional to dose was observed.</paragraph>
                        <paragraph>The pharmacokinetic parameters of total irinotecan and total SN-38 following the administration of ONIVYDE 70 mg/m<sup>2</sup> as a single agent or part of combination chemotherapy are presented in Table 7.</paragraph>
                        <table width="95%">
                           <caption>Table 7 Summary of Geometric Mean (CV) Total Irinotecan and Total SN-38</caption>
                           <col width="11%" align="left" valign="middle"/>
                           <col width="12%" align="center" valign="middle"/>
                           <col width="11%" align="center" valign="top"/>
                           <col width="11%" align="center" valign="top"/>
                           <col width="11%" align="center" valign="top"/>
                           <col width="11%" align="center" valign="top"/>
                           <col width="11%" align="center" valign="top"/>
                           <col width="11%" align="center" valign="top"/>
                           <col width="11%" align="center" valign="top"/>
                           <thead>
                              <tr styleCode="Botrule">
                                 <th styleCode="Lrule Rrule" rowspan="2" align="center" valign="middle">Dose<br/> (mg/m<sup>2</sup>)</th>
                                 <th styleCode="Rrule" align="center">Descriptive Statistics</th>
                                 <th styleCode="Rrule" colspan="4" align="center" valign="middle">Total Irinotecan</th>
                                 <th styleCode="Rrule" colspan="3" align="center" valign="middle">Total SN-38</th>
                              </tr>
                              <tr styleCode="Botrule">
                                 <th styleCode="Lrule Rrule"/>
                                 <th styleCode="Rrule" align="center">C<sub>max</sub>
                                    <br/>[Âµg/mL]</th>
                                 <th styleCode="Rrule" align="center">AUC<sub>SS</sub>
                                    <br/>[dayâÂµg/mL]</th>
                                 <th styleCode="Rrule" align="center">t<sub>1/2</sub>
                                    <br/>[day]</th>
                                 <th styleCode="Rrule" align="center">V<br/>[L]</th>
                                 <th styleCode="Rrule" align="center">C<sub>max</sub>
                                    <br/>[ng/mL]</th>
                                 <th styleCode="Rrule" align="center">AUC<sub>SS</sub>
                                    <br/>[dayâng/mL]</th>
                                 <th styleCode="Rrule" align="center">V<br/>[L]</th>
                              </tr>
                           </thead>
                           <tfoot>
                              <tr>
                                 <td align="left" colspan="9">AUC<sub>SS</sub>: Area under the plasma concentration curve at steady-state</td>
                              </tr>
                              <tr>
                                 <td align="left" colspan="9">t<sub>1/2</sub>: Terminal elimination half-life</td>
                              </tr>
                              <tr>
                                 <td align="left" colspan="9">V: Volume of distribution</td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" rowspan="2" align="left" valign="top">50</td>
                                 <td styleCode="Rrule" align="left">Geometric Mean</td>
                                 <td styleCode="Rrule">25.1</td>
                                 <td styleCode="Rrule">37.8</td>
                                 <td styleCode="Rrule">1.93</td>
                                 <td styleCode="Rrule">3.63</td>
                                 <td styleCode="Rrule">2.09</td>
                                 <td styleCode="Rrule">12.1</td>
                                 <td styleCode="Rrule">3.46</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" align="left">CV (%)</td>
                                 <td styleCode="Rrule">18.5	</td>
                                 <td styleCode="Rrule">73.6	</td>
                                 <td styleCode="Rrule">14</td>
                                 <td styleCode="Rrule">33.5</td>
                                 <td styleCode="Rrule">42.1</td>
                                 <td styleCode="Rrule">46.6</td>
                                 <td styleCode="Rrule">35.5</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule Botrule" align="left" valign="top" rowspan="2">70</td>
                                 <td styleCode="Lrule Rrule" align="left">Geometric Mean</td>
                                 <td styleCode="Rrule">30.8</td>
                                 <td styleCode="Rrule">50.4</td>
                                 <td styleCode="Rrule">1.87</td>
                                 <td styleCode="Rrule">4.23</td>
                                 <td styleCode="Rrule">2.64</td>
                                 <td styleCode="Rrule">14.7</td>
                                 <td styleCode="Rrule">4.06</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule" align="left">CV (%)</td>
                                 <td styleCode="Rrule">19.7</td>
                                 <td styleCode="Rrule">75.3</td>
                                 <td styleCode="Rrule">26.4</td>
                                 <td styleCode="Rrule">28.1</td>
                                 <td styleCode="Rrule">64.5</td>
                                 <td styleCode="Rrule">58</td>
                                 <td styleCode="Rrule">29.4</td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20241227"/>
                     <component>
                        <section>
                           <id root="02302225-4cba-4403-bb49-88826c54af92"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Distribution</content>
                              </paragraph>
                              <paragraph>Direct measurement of irinotecan liposome showed that 95% of irinotecan remains liposome -encapsulated, and the ratios between total and encapsulated forms did not change with time from 0 to 170 hours post-dose. The mean volume of distribution is summarized in Table 7.</paragraph>
                              <paragraph>Plasma protein binding is &lt;0.44% of the total irinotecan in ONIVYDE. </paragraph>
                           </text>
                           <effectiveTime value="20241227"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="95f0d1c5-805c-4ec9-9f64-7e7195031f65"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Elimination</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20241227"/>
                           <component>
                              <section>
                                 <id root="b8e29372-00d2-4fc6-b871-6c81ebfdbe98"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Metabolism</content>
                                    </paragraph>
                                    <paragraph>The metabolism of irinotecan liposome has not been evaluated. Irinotecan is subject to extensive metabolic conversion by various enzyme systems, including carboxylesterases to form the active metabolite SN-38, and UGT1A1 mediating glucuronidation of SN-38 to form the inactive glucuronide metabolite SN-38G. Irinotecan can also undergo CYP3A4-mediated oxidative metabolism to several inactive oxidation products, one of which can be hydrolyzed by carboxylesterase to release SN-38. In the population PK analysis of irinotecan liposome, UGT1A1*28 7/7 homozygous status (10.6%) had no effect on SN-38 clearance compared with patients not homozygous for UGT1A1*28 7/7.</paragraph>
                                 </text>
                                 <effectiveTime value="20241227"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="8fb8631c-3b63-4e79-ab4d-ea1b0236dfa5"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Excretion</content>
                                    </paragraph>
                                    <paragraph>The disposition of ONIVYDE has not been elucidated in humans. Following administration of irinotecan HCl, the urinary excretion of irinotecan is 11 to 20%; SN-38, &lt;1%; and SN-38 glucuronide, 3%. The cumulative biliary and urinary excretion of irinotecan and its metabolites (SN-38 and SN-38 glucuronide), over a period of 48 hours following administration of irinotecan HCl in two patients, ranged from approximately 25% (100 mg/m<sup>2</sup>) to 50% (300 mg/m<sup>2</sup>).</paragraph>
                                 </text>
                                 <effectiveTime value="20241227"/>
                              </section>
                           </component>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="4a1eb8c7-9a1f-483e-a000-9581c013ccff"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Specific Populations</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20241227"/>
                           <component>
                              <section>
                                 <id root="5b31ba69-bcbe-4b5d-9a3b-19f5a4694ebc"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Age, Sex, Ethnicity, Renal and Hepatic Impairment:</content>
                                    </paragraph>
                                    <paragraph>The population pharmacokinetic analyses suggest that age (20 to 87 years) and BSA (1.15 to 2.88 m<sup>2</sup>) had no clinically meaningful effect on the exposure of irinotecan and SN-38.</paragraph>
                                    <paragraph>Irinotecan and SN-38 AUC in female patients were 28% and 32% higher, respectively, than those in male patients. Irinotecan AUC in patients of Asian ethnicity were 32% lower than that in non-Asian patients. The exposures of irinotecan and SN-38 in patients with mild or moderate renal impairment were comparable to patients with normal renal function after adjusting for BSA. The exposures of irinotecan and SN-38 in patients with mild hepatic impairment (based on NCI score) were comparable to patients with normal hepatic function. There was insufficient data in patients with severe renal impairment (CLcr &lt; 30 mL/min) or in patients with moderate and severe hepatic impairment to assess their effects on the exposures of irinotecan and SN-38. Increased AST/ALT had no effect on irinotecan clearance; however, increased bilirubin level was associated with lower SNâ38 clearance. SN-38 AUC was increased by 32% in patients with bilirubin level of 1.14 mg/dL (95<sup>th</sup> of the overall population) compared with that of median bilirubin level of 0.44 mg/dL. No data are available in patients with bilirubin &gt;2.8 mg/dL.</paragraph>
                                 </text>
                                 <effectiveTime value="20241227"/>
                              </section>
                           </component>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="1ba98534-90eb-49a0-b433-7643bb0db62d"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Drug Interactions</content>
                              </paragraph>
                              <paragraph>In a population pharmacokinetic analysis, the pharmacokinetics of total irinotecan and total SN-38 were not altered by the co-administration of fluorouracil/leucovorin. In Study MMâ398â07â02â03 and NAPOLI-3, irinotecan AUC was decreased by 33% and SN-38 C<sub>max</sub> increased by 23% following co-administration with oxaliplatin. </paragraph>
                              <paragraph>Following administration of irinotecan HCl, dexamethasone (moderate CYP3A4 inducer) does not alter the pharmacokinetics of irinotecan.</paragraph>
                              <paragraph>In vitro studies indicate that irinotecan, SN-38 and another metabolite, aminopentane carboxylic acid (APC), do not inhibit cytochrome P-450 isozymes.</paragraph>
                           </text>
                           <effectiveTime value="20241227"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S12.5">
                     <id root="dbefec6a-295b-4400-90ea-3389701f040b"/>
                     <code code="66106-6" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOGENOMICS SECTION"/>
                     <title>12.5 Pharmacogenomics</title>
                     <text>
                        <paragraph>Individuals who are homozygous for the UGT1A1*28 allele are at increased risk for neutropenia from irinotecan HCl. In NAPOLI-1, patients homozygous for the UGT1A1*28 allele (N=7) initiated ONIVYDE at a reduced dose of 50 mg/m<sup>2</sup> in combination with FU/LV. The frequency of Grade 3 or 4 neutropenia in these patients [2 of 7 (28.6%)] was similar to the frequency in patients not homozygous for the UGT1A1*28 allele who received a starting dose of ONIVYDE of 70 mg/m<sup>2</sup> [30 of 110 (27.3%)]. In NAPOLI-3, patients homozygous for the UGT1A1*28 allele (N = 39) initiated ONIVYDE at the same starting dose of 50 mg/m<sup>2</sup> as patients not homozygous for the UGT1A1*28 allele (N = 328). The frequency of Grade 3 or 4 neutropenia was 23% in patients homozygous for the UGT1A1*28 allele and 13% in patients not homozygous for the UGT1A1*28 allele. The frequency of dose reduction of ONIVYDE due to treatment-emergent adverse effects was 59% versus 51% in patients homozygous versus non-homozygous for the UGT1A1*28 allele.</paragraph>
                     </text>
                     <effectiveTime value="20241227"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S13">
               <id root="e304d628-456e-4baa-a8d1-13ed673385fb"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13 NONCLINICAL TOXICOLOGY</title>
               <effectiveTime value="20241227"/>
               <component>
                  <section ID="S13.1">
                     <id root="aedb03ec-77d2-4145-be09-9d8fca8f6a0b"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</title>
                     <text>
                        <paragraph>No studies have been performed to assess the potential of irinotecan liposome for carcinogenicity, genotoxicity or impairment of fertility. Intravenous administration of irinotecan hydrochloride to rats once weekly for 13 weeks followed by a 91-week recovery period resulted in a significant linear trend between irinotecan HCl dosage and the incidence of combined uterine horn endometrial stromal polyps and endometrial stromal sarcomas. Irinotecan HCl was clastogenic both in vitro (chromosome aberrations in Chinese hamster ovary cells) and in vivo (micronucleus test in mice). Neither irinotecan nor its active metabolite, SN-38, was mutagenic in the in vitro Ames assay.</paragraph>
                        <paragraph>Dedicated fertility studies have not been performed with irinotecan liposome injection. Atrophy of male and female reproductive organs was observed in dogs receiving irinotecan liposome injection every 3 weeks at doses equal to or greater than 15 mg/kg, (approximately 3 times the clinical exposure of irinotecan following administration to ONIVYDE dosed at 70 mg/m<sup>2</sup>) for a total of 6 doses. No significant adverse effects on fertility and general reproductive performance were observed after intravenous administration of irinotecan HCl in doses of up to 6 mg/kg/day to rats; however, atrophy of male reproductive organs was observed after multiple daily irinotecan HCl doses both in rodents at 20 mg/kg (approximately 0.007 times the clinical irinotecan exposure following ONIVYDE administration at 70 mg/m<sup>2</sup>) and in dogs at 0.4 mg/kg (0.0007 times the clinical exposure to irinotecan following administration of ONIVYDE).</paragraph>
                     </text>
                     <effectiveTime value="20241227"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S14">
               <id root="0c796378-d1be-44ff-80d0-b8a45b5980c5"/>
               <code code="34092-7" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL STUDIES SECTION"/>
               <title>14 CLINICAL STUDIES</title>
               <effectiveTime value="20241227"/>
               <component>
                  <section>
                     <id root="5849c1fb-530d-442d-870b-04cdcc9b2702"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Pancreatic Adenocarcinoma</content>
                        </paragraph>
                        <paragraph>In Combination with Oxaliplatin, Fluorouracil and Leucovorin for First-Line Treatment of Metastatic Pancreatic Adenocarcinoma </paragraph>
                        <paragraph>The efficacy of ONIVYDE in combination with oxaliplatin, fluorouracil and leucovorin (NALIRIFOX) was evaluated in NAPOLI 3 (NCT04083235), a randomized, multicenter, open-label, active-controlled trial in 770 patients with metastatic pancreatic adenocarcinoma who had not previously received chemotherapy in the metastatic setting. Randomization was stratified by region, liver metastases and ECOG performance status. Patients were randomized (1:1) to receive one of the following treatment arm:</paragraph>
                        <list listType="unordered" styleCode="disc">
                           <item>NALIRIFOX: ONIVYDE 50 mg/m<sup>2</sup> as an intravenous infusion over 90 minutes, followed by oxaliplatin 60 mg/m<sup>2</sup> as an intravenous infusion over 120 minutes, followed by leucovorin 400 mg/m<sup>2</sup> intravenously over 30 minutes, followed by fluorouracil 2400 mg/m<sup>2</sup> intravenously over 46 hours, every 2 weeks. </item>
                           <item>Gem+NabP: Nab-paclitaxel 125 mg/m<sup>2</sup> as an intravenous infusion over 35 minutes, followed by gemcitabine 1000 mg/m<sup>2</sup> intravenously over 30 minutes on days 1, 8 and 15 of each 28-day cycle.</item>
                        </list>
                        <paragraph>Patients homozygous for the UGT1A1*28 allele initiated ONIVYDE at the same dose (50 mg/m<sup>2</sup> ONIVYDE). Treatment continued until RECIST v1.1 defined disease progression or unacceptable toxicity. Tumor status assessments were conducted at baseline and every 8 weeks thereafter as assessed by the investigator according to RECIST v1.1.</paragraph>
                        <paragraph>The main efficacy outcome measure was overall survival (OS). Additional efficacy measures were investigator-assessed progression-free survival (PFS) and objective response rate (ORR).</paragraph>
                        <paragraph>Baseline demographic and patient characteristics were: median age of 65 years (range: 20-85); 50% age 65 or older; 56% male; 83% White, 4.9% Asian, 2.5% Black or African American, 0.4% multiple race, 0.3% American Indian or Alaska Native; 0.1% Native Hawaiian or other Pacific Islander, 1.7% other, 7% not reported; and 82% non-Hispanic, 10% Hispanic, 8% not reported. ECOG performance status was 0 or 1 in 44% and 56% of patients, respectively; 80% had liver metastases.</paragraph>
                        <paragraph>NAPOLI 3 demonstrated a statistically significant improvement in OS and PFS for the NALIRIFOX arm over Gem+NabP arm as summarized in Table 8 and Figure 1.</paragraph>
                        <table width="75%" ID="Table8">
                           <caption>Table 8	Efficacy Results of All Randomized Patients in NAPOLI 3</caption>
                           <col width="40%" align="left" valign="middle"/>
                           <col width="30%" align="center" valign="middle"/>
                           <col width="30%" align="center" valign="middle"/>
                           <thead>
                              <tr>
                                 <th styleCode="Lrule Rrule"/>
                                 <th styleCode="Rrule">NALIRIFOX<footnote ID="ft8">NALIRIFOX= ONIVYDE+oxaliplatin/5-fluorouracil/leucovorin; Gem+NabP=gemcitabine+nab-paclitaxel; CI=confidence interval</footnote>
                                    <br/>(N=383)</th>
                                 <th styleCode="Rrule">Gem+NabP<br/>(N=387)</th>
                              </tr>
                           </thead>
                           <tfoot>
                              <tr>
                                 <td align="left" colspan="3">**Based on the stratified Cox proportional hazard model; stratified by ECOG PS (0 vs. 1), region (North America vs. East Asia vs. Rest of the world), and liver metastases (yes vs. no) per interaction web response system</td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" colspan="3">
                                    <content styleCode="bold">Overall Survival</content>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Â Â Number of Deaths, n (%)</td>
                                 <td styleCode="Rrule">259 (68)</td>
                                 <td styleCode="Rrule">285 (74)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Â Â Median Overall Survival (months)</td>
                                 <td styleCode="Rrule">11.1</td>
                                 <td styleCode="Rrule">9.2</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Â Â (95% CI)</td>
                                 <td styleCode="Rrule">(10.0, 12.1)</td>
                                 <td styleCode="Rrule">(8.3, 10.6)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Â Â Hazard Ratio (95% CI) <footnoteRef IDREF="ft8"/>
                                 </td>
                                 <td styleCode="Rrule" colspan="2">0.84 (0.71, 0.99)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Â Â p-value <footnote ID="ft8a">Based on stratified log-rank test.</footnote>
                                 </td>
                                 <td styleCode="Rrule" colspan="2">0.0403</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" colspan="3">
                                    <content styleCode="bold">Progression-Free Survival</content>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Â Â Death or Progression, n (%)</td>
                                 <td styleCode="Rrule">249 (65)</td>
                                 <td styleCode="Rrule">259 (67)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Â Â Median Progression-Free Survival (months)</td>
                                 <td styleCode="Rrule">7.4</td>
                                 <td styleCode="Rrule">5.6</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Â Â (95% CI)</td>
                                 <td styleCode="Rrule">(6.0, 7.7)</td>
                                 <td styleCode="Rrule">(5.3, 5.8)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Â Â Hazard Ratio (95% CI) <footnoteRef IDREF="ft8"/>
                                 </td>
                                 <td styleCode="Rrule" colspan="2">0.70 (0.59, 0.85)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Â Â P-value <footnoteRef IDREF="ft8a"/>
                                 </td>
                                 <td styleCode="Rrule" colspan="2">0.0001</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" colspan="3">
                                    <content styleCode="bold">Objective Response Rate <footnote>ORR result was not statistically significant.</footnote>
                                    </content>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Â Â ORR (95% CI)</td>
                                 <td styleCode="Rrule">41.8 (36.8, 46.9)</td>
                                 <td styleCode="Rrule">36.2 (31.4, 41.2)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Â Â Â Â CR, n (%)</td>
                                 <td styleCode="Rrule">1 (0.3)</td>
                                 <td styleCode="Rrule">1 (0.3)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule">Â Â Â Â PR, n (%)</td>
                                 <td styleCode="Rrule">159 (41.5)</td>
                                 <td styleCode="Rrule">139 (35.9)</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>
                           <content styleCode="bold">Figure 1	Kaplan-Meier Curve for Overall Survival in all randomized Patients in NAPOLI 3</content>
                        </paragraph>
                        <renderMultiMedia referencedObject="MM2"/>
                     </text>
                     <effectiveTime value="20241227"/>
                     <component>
                        <observationMedia ID="MM2">
                           <text>Figure 1</text>
                           <value xsi:type="ED" mediaType="image/jpeg">
                              <reference value="onivyde-02.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="1059a36f-dc8d-46ea-b3c1-951e3624acb9"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Previously treated metastatic pancreatic adenocarcinoma in combination with fluorouracil and leucovorin</content>
                        </paragraph>
                        <paragraph>The efficacy of ONIVYDE was evaluated in NAPOLI-1 (NCT01494506), a three-arm, randomized, open-label trial in patients with metastatic pancreatic adenocarcinoma with documented disease progression, after gemcitabine or gemcitabine-based therapy. Key eligibility criteria included Karnofsky Performance Status (KPS) â¥70, serum bilirubin within institution limits of normal, and albumin â¥3.0 g/dL. Patients were randomized to receive ONIVYDE plus fluorouracil/leucovorin (ONIVYDE/FU/LV), ONIVYDE, or fluorouracil/leucovorin (FU/LV). Randomization was stratified by ethnicity (White vs. East Asian vs. other), KPS (70-80 vs. 90-100), and baseline albumin level (â¥ 4 g/dL vs. 3.0-3.9 g/dL). Patients randomized to ONIVYDE/FU/LV received ONIVYDE 70 mg/m<sup>2</sup> as an intravenous infusion over 90 minutes, followed by leucovorin 400 mg/m<sup>2</sup> intravenously over 30 minutes, followed by fluorouracil 2400 mg/m<sup>2</sup> intravenously over 46 hours, every 2 weeks. The ONIVYDE dose of 70 mg/m<sup>2</sup> is based on irinotecan free base (equivalent to 80 mg/m<sup>2</sup> of irinotecan as the hydrochloride trihydrate). Patients randomized to ONIVYDE as a single agent received ONIVYDE 100 mg/m<sup>2</sup> as an intravenous infusion over 90 minutes every 3 weeks. Patients randomized to FU/LV received leucovorin 200 mg/m<sup>2</sup> intravenously over 30 minutes, followed by fluorouracil 2000 mg/m<sup>2</sup> intravenously over 24 hours, administered on Days 1, 8, 15 and 22 of a 6-week cycle. Patients homozygous for the UGT1A1*28 allele initiated ONIVYDE at a reduced dose (50 mg/m<sup>2</sup> ONIVYDE, if given with FU/LV or 70 mg/m<sup>2</sup> ONIVYDE as a single agent). When ONIVYDE was withheld or discontinued for adverse reactions, FU was also withheld or discontinued. When the dose of ONIVYDE was reduced for adverse reactions, the dose of FU was reduced by 25%. Treatment continued until disease progression or unacceptable toxicity.</paragraph>
                        <paragraph>The major efficacy outcome measure was overall survival (OS) with two pair-wise comparisons: ONIVYDE versus FU/LV and ONIVYDE/FU/LV versus FU/LV. Additional efficacy outcome measures were progression-free survival (PFS) and objective response rate (ORR). Tumor status assessments were conducted at baseline and every 6 weeks thereafter. The trial was initiated as a two-arm study and amended after initiation to include a third arm (ONIVYDE/FU/LV). The comparisons between the ONIVYDE/FU/LV and the FU/LV arms are limited to patients enrolled in the FU/LV arm after this protocol amendment.</paragraph>
                        <paragraph>Four hundred seventeen patients were randomized to: ONIVYDE/FU/LV (N=117), ONIVYDE (N=151), or FU/LV (N=149). Baseline demographics and tumor characteristics for the 236 patients randomized to ONIVYDE/FU/LV or FU/LV (N=119) after the addition of the third arm to the study were a median age of 63 years (range 34-81 years) and with 41% â¥ 65 years of age; 58% were men; 63% were White, 30% were Asian, 3% were Black or African American, and 5% were other. Mean baseline albumin level was 3.97 g/dL, and baseline KPS was 90-100 in 53% of patients. Disease characteristics included liver metastasis (67%) and lung metastasis (31%). A total of 13% of patients received gemcitabine in the neoadjuvant/adjuvant setting only, 55% of patients had 1 prior line of therapy for metastatic disease, and 33% of patients had 2 or more prior lines of therapy for metastatic disease. All patients received prior gemcitabine (alone or in combination with another agent), 54% received prior gemcitabine in combination with another agent, and 13% received prior gemcitabine in combination with nab-paclitaxel.</paragraph>
                        <paragraph>NAPOLI-1 demonstrated a statistically significant improvement in overall survival for the ONIVYDE/FU/LV arm over the FU/LV arm as summarized in Table 9 and Figure 2.</paragraph>
                        <paragraph>There was no improvement in overall survival for the ONIVYDE arm over the FU/LV arm (hazard ratio=1.00, p-value=0.97 (two-sided log-rank test)).</paragraph>
                        <table width="75%" ID="Table9">
                           <caption>Table 9	Efficacy Results from NAPOLI-1<footnote>FU/LV=5-fluorouracil/leucovorin; CI=confidence interval</footnote>
                           </caption>
                           <col width="40%" align="left" valign="middle"/>
                           <col width="30%" align="center" valign="middle"/>
                           <col width="30%" align="center" valign="middle"/>
                           <thead>
                              <tr>
                                 <th styleCode="Lrule Rrule"/>
                                 <th styleCode="Rrule">ONIVYDE/FU/LV<br/>(N=117)</th>
                                 <th styleCode="Rrule">FU/LV<br/>(N=119)</th>
                              </tr>
                           </thead>
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" colspan="3">
                                    <content styleCode="bold">Overall Survival</content>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Â Â Number of Deaths, n (%)</td>
                                 <td styleCode="Rrule">77 (66)</td>
                                 <td styleCode="Rrule">86 (72)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Â Â Median Overall Survival (months)</td>
                                 <td styleCode="Rrule">6.1</td>
                                 <td styleCode="Rrule">4.2</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Â Â (95% CI)</td>
                                 <td styleCode="Rrule">(4.8, 8.5)</td>
                                 <td styleCode="Rrule">(3.3, 5.3)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Â Â Hazard Ratio (95% CI)</td>
                                 <td styleCode="Rrule" colspan="2">0.68 (0.50, 0.93)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Â Â p-value (log-rank test)</td>
                                 <td styleCode="Rrule" colspan="2">0.014</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" colspan="3">
                                    <content styleCode="bold">Progression-Free Survival</content>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Â Â Death or Progression, n (%)</td>
                                 <td styleCode="Rrule">83 (71)</td>
                                 <td styleCode="Rrule">94 (79)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Â Â Median Progression-Free Survival (months)</td>
                                 <td styleCode="Rrule">3.1</td>
                                 <td styleCode="Rrule">1.5</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Â Â (95% CI)</td>
                                 <td styleCode="Rrule">(2.7, 4.2)</td>
                                 <td styleCode="Rrule">(1.4, 1.8)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Â Â Hazard Ratio (95% CI)</td>
                                 <td styleCode="Rrule" colspan="2">0.55 (0.41, 0.75)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" colspan="3">
                                    <content styleCode="bold">Objective Response Rate</content>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Â Â Confirmed Complete or Partial Response n (%)</td>
                                 <td styleCode="Rrule">9 (7.7%)</td>
                                 <td styleCode="Rrule">1 (0.8%) </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>
                           <content styleCode="bold">Figure 2	Kaplan-Meier Curve for Overall Survival in all randomized Patients in NAPOLI-1</content>
                        </paragraph>
                        <renderMultiMedia referencedObject="MM3"/>
                     </text>
                     <effectiveTime value="20241227"/>
                     <component>
                        <observationMedia ID="MM3">
                           <text>Figure 2</text>
                           <value xsi:type="ED" mediaType="image/jpeg">
                              <reference value="onivyde-03.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S15">
               <id root="a156cdf7-fcf1-42e8-9a01-69b52228cb7e"/>
               <code code="34093-5" codeSystem="2.16.840.1.113883.6.1" displayName="REFERENCES SECTION"/>
               <title>15 REFERENCES</title>
               <text>
                  <paragraph>1. OSHA Hazardous Drugs. <content styleCode="italics">OSHA.</content> http://www.osha.gov/SLTC/hazardousdrugs/index.html</paragraph>
               </text>
               <effectiveTime value="20241227"/>
            </section>
         </component>
         <component>
            <section ID="S16">
               <id root="67265730-3eaa-410b-a6ce-ceae4e1f39dd"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16 HOW SUPPLIED/STORAGE AND HANDLING</title>
               <effectiveTime value="20241227"/>
               <component>
                  <section>
                     <id root="d9ee3636-da2f-43de-8fe3-50b3a33f1abb"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">How Supplied</content>
                        </paragraph>
                        <paragraph>ONIVYDE is available in a single-dose vial containing 43 mg irinotecan free base at a concentration of 4.3 mg/mL.</paragraph>
                        <paragraph>NDC: 15054-0043-1</paragraph>
                     </text>
                     <effectiveTime value="20241227"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="107df1c2-e539-4360-a1cb-066065163ed0"/>
                     <code code="44425-7" codeSystem="2.16.840.1.113883.6.1" displayName="STORAGE AND HANDLING SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Storage and Handling</content>
                        </paragraph>
                        <paragraph>Store ONIVYDE at 2ÂºC to 8ÂºC (36Â°F to 46Â°F). Do NOT freeze. Protect from light.</paragraph>
                        <paragraph>ONIVYDE is a hazardous drug. Follow applicable special handling and disposal procedures.<sup>1</sup>
                        </paragraph>
                     </text>
                     <effectiveTime value="20241227"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S17">
               <id root="f1f27080-470c-4290-8320-b9ecae04242c"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>17 PATIENT COUNSELING INFORMATION</title>
               <text>
                  <paragraph>Advise patients of the following:</paragraph>
               </text>
               <effectiveTime value="20241227"/>
               <component>
                  <section>
                     <id root="0241013b-e65a-460b-9e60-cf26dc04dbff"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline italics">Severe Neutropenia</content>
                        </paragraph>
                        <paragraph>Advise patients of the risk of neutropenia leading to severe and life-threatening infections and the need for monitoring of blood counts. Instruct patients to contact their healthcare provider immediately if experiencing signs of infection, such as fever, chills, dizziness, or shortness of breath <content styleCode="italics">[see <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20241227"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="45ac680b-98b0-4fba-b7f7-f33648d75ea2"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline italics">Severe Diarrhea</content>
                        </paragraph>
                        <paragraph>Inform patients of the risk of severe and life-threatening diarrhea. Advise patients to stop lactose-containing products, maintain hydration, and eat frequent small meals with a low-fat diet. Advise patients to contact their healthcare provider if they experience persistent vomiting or diarrhea; black or bloody stools; or symptoms of dehydration such as lightheadedness, dizziness, or faintness <content styleCode="italics">[see <linkHtml href="#S5.2">Warnings and Precautions (5.2)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20241227"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="b29a559c-f659-48d0-a33f-b983b954e537"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline italics">Interstitial Lung Disease</content>
                        </paragraph>
                        <paragraph>Inform patients of the potential risk of ILD. Advise patients to contact their healthcare provider as soon as possible for new onset cough or dyspnea <content styleCode="italics">[see <linkHtml href="#S5.3">Interstitial Lung Disease (5.3)</linkHtml>].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20241227"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="32518203-885d-4d23-a31c-9005bca86a79"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline italics">Hypersensitivity to irinotecan HCl or ONIVYDE</content>
                        </paragraph>
                        <paragraph>Advise patients of the potential risk of severe hypersensitivity and that ONIVYDE is contraindicated in patients with a history of severe allergic reactions with irinotecan HCl or ONIVYDE. Instruct patients to seek immediate medical attention for signs of severe hypersensitivity reaction such as chest tightness; shortness of breath; wheezing; dizziness or faintness; or swelling of the face, eyelids, or lips <content styleCode="italics">[see <linkHtml href="#S4">Contraindications (4)</linkHtml> and <linkHtml href="#S5.4">Warnings and Precautions (5.4)</linkHtml>].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20241227"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="413f505e-398d-4691-acd5-bbc329f204f1"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline italics">Females and males of reproductive potential</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20241227"/>
                     <component>
                        <section>
                           <id root="dca96524-5c97-4fcf-8c0c-6a941762a5f9"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Embryo-fetal toxicity</content>: Inform females of reproductive potential of the potential risk to a fetus, to use effective contraception during treatment and for seven months after the last dose, and to inform their healthcare provider of a known or suspected pregnancy <content styleCode="italics">[see <linkHtml href="#S5.5">Warnings and Precautions (5.5)</linkHtml>, <linkHtml href="#S8.1">Use in Specific Populations (8.1</linkHtml>, <linkHtml href="#S8.3">8.3)</linkHtml>]</content>.</paragraph>
                           </text>
                           <effectiveTime value="20241227"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="8b09cc2b-c1f1-46a1-9bbf-b30d32496ea4"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Contraception</content>: Advise male patients with female partners of reproductive potential to use condoms during treatment with ONIVYDE and for four months after the last dose <content styleCode="italics">[see <linkHtml href="#S8.3">Females and Males of Reproductive Potential (8.3)</linkHtml>].</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20241227"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="c638bf3e-6d93-4a5a-9a56-3af1d9f66c09"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline italics">Lactation</content>
                        </paragraph>
                        <paragraph>Advise women not to breastfeed during treatment with ONIVYDE and for one month after the last dose <content styleCode="italics">[see <linkHtml href="#S8.2">Use in Special Populations (8.2)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20241227"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="97c9589b-22da-4d0d-89a0-c7b4a5dce2c3"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>Manufactured for:<br/>Ipsen Biopharmaceuticals, Inc. Cambridge, MA 02142<br/>ONIVYDE is a registered trademark of Ipsen Biopharm Ltd.</paragraph>
                     </text>
                     <effectiveTime value="20241227"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="637b513b-101f-40e0-a7df-52e02484dd4b"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL - 43 mg/10 mL Vial Label</title>
               <text>
                  <paragraph>NDC 15054-0043-1<br/>Rx Only</paragraph>
                  <paragraph>Onivyde<sup>Â®</sup>
                     <br/>(irinotecan liposome injection)</paragraph>
                  <paragraph>43 mg/10 mL<br/>(4.3 mg/mL)</paragraph>
                  <paragraph>For Intravenous Infusion After Dilution<br/>Single Dose Vial<br/>Discard Unused Portion</paragraph>
                  <paragraph>Liposomal Formulation<br/>Do Not Substitute For<br/>Irinotecan Hydrochloride</paragraph>
                  <renderMultiMedia referencedObject="MM4"/>
               </text>
               <effectiveTime value="20241227"/>
               <component>
                  <observationMedia ID="MM4">
                     <text>PRINCIPAL DISPLAY PANEL - 43 mg/10 mL Vial Label</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="onivyde-04.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="b0ba8e12-f44c-488f-abc8-fb9db58e45dc"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL - 43 mg/10 mL Vial Carton</title>
               <text>
                  <paragraph>NDC 15054-0043-1<br/>Rx Only</paragraph>
                  <paragraph>onivyde<sup>Â®</sup>
                     <br/>(irinotecan liposome injection)</paragraph>
                  <paragraph>43 mg/10 mL<br/>(4.3 mg/mL)</paragraph>
                  <paragraph>For Intravenous Infusion After Dilution</paragraph>
                  <paragraph>Warning: Hazardous drug</paragraph>
                  <paragraph>Single Dose Vial<br/>Discard Unused Portion</paragraph>
                  <paragraph>Liposomal Formulation<br/>Do Not Substitute For Irinotecan Hydrochloride</paragraph>
                  <renderMultiMedia referencedObject="MM5"/>
               </text>
               <effectiveTime value="20241227"/>
               <component>
                  <observationMedia ID="MM5">
                     <text>PRINCIPAL DISPLAY PANEL - 43 mg/10 mL Vial Carton</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="onivyde-05.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>